FI82696B - PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PROPERTIES OF PTERIDINER. - Google Patents
PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PROPERTIES OF PTERIDINER. Download PDFInfo
- Publication number
- FI82696B FI82696B FI854862A FI854862A FI82696B FI 82696 B FI82696 B FI 82696B FI 854862 A FI854862 A FI 854862A FI 854862 A FI854862 A FI 854862A FI 82696 B FI82696 B FI 82696B
- Authority
- FI
- Finland
- Prior art keywords
- group
- pteridine
- phenyl
- piperazino
- yield
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000000144 pharmacologic effect Effects 0.000 title description 5
- -1 piperazino group Chemical group 0.000 claims description 99
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 150000003195 pteridines Chemical class 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- CYMCSLFWXQJBHU-UHFFFAOYSA-N n-benzyl-6-phenyl-2-piperazin-1-yl-4-thiomorpholin-4-ylpteridin-7-amine Chemical compound C=1C=CC=CC=1CNC(C(=NC1=2)C=3C=CC=CC=3)=NC1=NC(N1CCNCC1)=NC=2N1CCSCC1 CYMCSLFWXQJBHU-UHFFFAOYSA-N 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 135
- 238000002844 melting Methods 0.000 description 76
- 230000008018 melting Effects 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000007792 addition Methods 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 150000002168 ethanoic acid esters Chemical class 0.000 description 11
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 10
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940093915 gynecological organic acid Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- WSYXJPXVIWXEKQ-UHFFFAOYSA-N 4-(2,7-dichloro-6-phenylpteridin-4-yl)thiomorpholine Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(Cl)=NC=1N1CCSCC1 WSYXJPXVIWXEKQ-UHFFFAOYSA-N 0.000 description 3
- LDXZXENTEQVNJT-UHFFFAOYSA-N 4-(7-chloro-4-morpholin-4-yl-6-phenylpteridin-2-yl)piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(N2CCN(CC2)C=O)=NC=1N1CCOCC1 LDXZXENTEQVNJT-UHFFFAOYSA-N 0.000 description 3
- GAWKTFFNBBOGFS-UHFFFAOYSA-N 4-[7-chloro-4-(1-oxo-1,4-thiazinan-4-yl)-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(N2CCN(CC2)C=O)=NC=1N1CCS(=O)CC1 GAWKTFFNBBOGFS-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RIBWUHCWCPYSQW-UHFFFAOYSA-N 2-piperazin-1-ylpteridine Chemical class C1CNCCN1C1=NC=C(N=CC=N2)C2=N1 RIBWUHCWCPYSQW-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- GJBIGLFKYRNPRQ-UHFFFAOYSA-N 4-(2,7-dichloro-6-phenylpteridin-4-yl)morpholine Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(Cl)=NC=1N1CCOCC1 GJBIGLFKYRNPRQ-UHFFFAOYSA-N 0.000 description 2
- SWQVUKRKXPTFJY-UHFFFAOYSA-N 4-(2,7-dichloropteridin-4-yl)morpholine Chemical compound N=1C(Cl)=NC2=NC(Cl)=CN=C2C=1N1CCOCC1 SWQVUKRKXPTFJY-UHFFFAOYSA-N 0.000 description 2
- CEQDHZLUCKTZDQ-UHFFFAOYSA-N 4-(2-chloro-4-morpholin-4-ylpteridin-7-yl)morpholine Chemical compound C=12N=CC(N3CCOCC3)=NC2=NC(Cl)=NC=1N1CCOCC1 CEQDHZLUCKTZDQ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- GLAMJFYGEMODFF-UHFFFAOYSA-N 4-[7-(benzylamino)-6-phenyl-4-thiomorpholin-4-ylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound C1CN(C=O)CCN1C1=NC(N2CCSCC2)=C(N=C(C(NCC=2C=CC=CC=2)=N2)C=3C=CC=CC=3)C2=N1 GLAMJFYGEMODFF-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UXVXHECNJUECPO-UHFFFAOYSA-N n,n-dimethyl-6-phenyl-2-piperazin-1-yl-4-pyrrolidin-1-ylpteridin-7-amine Chemical compound C=12N=C(C=3C=CC=CC=3)C(N(C)C)=NC2=NC(N2CCNCC2)=NC=1N1CCCC1 UXVXHECNJUECPO-UHFFFAOYSA-N 0.000 description 2
- KNDYYVVEFVWOOT-UHFFFAOYSA-N n-benzyl-2-chloro-4-piperidin-1-ylpteridin-7-amine Chemical compound C=12N=CC(NCC=3C=CC=CC=3)=NC2=NC(Cl)=NC=1N1CCCCC1 KNDYYVVEFVWOOT-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- MSSDTZLYNMFTKN-UHFFFAOYSA-N 1-Piperazinecarboxaldehyde Chemical compound O=CN1CCNCC1 MSSDTZLYNMFTKN-UHFFFAOYSA-N 0.000 description 1
- NWBJBMHJBACYGT-UHFFFAOYSA-N 2,4,7-trichloro-6-phenylpteridine Chemical compound ClC1=NC2=NC(Cl)=NC(Cl)=C2N=C1C1=CC=CC=C1 NWBJBMHJBACYGT-UHFFFAOYSA-N 0.000 description 1
- VQPKNENUIGMHNU-UHFFFAOYSA-N 2,4,7-trichloropteridine Chemical compound ClC1=NC(Cl)=NC2=NC(Cl)=CN=C21 VQPKNENUIGMHNU-UHFFFAOYSA-N 0.000 description 1
- RGKRHWLTEUVZHM-UHFFFAOYSA-N 2,7-dichloro-6-phenyl-4-piperidin-1-ylpteridine Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(Cl)=NC=1N1CCCCC1 RGKRHWLTEUVZHM-UHFFFAOYSA-N 0.000 description 1
- ILYDCKYNGFVQHZ-UHFFFAOYSA-N 2,7-dichloro-N,N-dimethyl-6-phenylpteridin-4-amine Chemical compound ClC1=NC2=NC(=C(N=C2C(=N1)N(C)C)C1=CC=CC=C1)Cl ILYDCKYNGFVQHZ-UHFFFAOYSA-N 0.000 description 1
- OJERFWUAMPYEMC-UHFFFAOYSA-N 2-[[7-(benzylamino)-2-chloropteridin-4-yl]-methylamino]ethanol Chemical compound C=1N=C2C(N(CCO)C)=NC(Cl)=NC2=NC=1NCC1=CC=CC=C1 OJERFWUAMPYEMC-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CKVPAYIYEWAHIB-UHFFFAOYSA-N 4-(2,7-dichloro-6-methyl-6H-pteridin-7-yl)morpholine Chemical compound ClC1=NC2=NC(C(N=C2C=N1)C)(N1CCOCC1)Cl CKVPAYIYEWAHIB-UHFFFAOYSA-N 0.000 description 1
- NSWWAJFJFVIFIY-UHFFFAOYSA-N 4-(2-chloro-6-methyl-4-morpholin-4-ylpteridin-7-yl)morpholine Chemical compound CC1=NC2=C(N3CCOCC3)N=C(Cl)N=C2N=C1N1CCOCC1 NSWWAJFJFVIFIY-UHFFFAOYSA-N 0.000 description 1
- NLYWGPYBUHRLLS-UHFFFAOYSA-N 4-(2-chloro-6-methyl-7-thiomorpholin-4-ylpteridin-4-yl)morpholine Chemical compound CC1=NC2=C(N3CCOCC3)N=C(Cl)N=C2N=C1N1CCSCC1 NLYWGPYBUHRLLS-UHFFFAOYSA-N 0.000 description 1
- XGWVNQNSJQGULB-UHFFFAOYSA-N 4-(4-morpholin-4-yl-2-piperazin-1-ylpteridin-7-yl)morpholine Chemical compound C1CNCCN1C1=NC(N2CCOCC2)=C(N=CC(=N2)N3CCOCC3)C2=N1 XGWVNQNSJQGULB-UHFFFAOYSA-N 0.000 description 1
- DUWXBAYNTVXXPX-UHFFFAOYSA-N 4-(6-methyl-2-piperazin-1-yl-7-thiomorpholin-4-ylpteridin-4-yl)morpholine Chemical compound CC1=NC2=C(N3CCOCC3)N=C(N3CCNCC3)N=C2N=C1N1CCSCC1 DUWXBAYNTVXXPX-UHFFFAOYSA-N 0.000 description 1
- JYKRPHPHUQAIPZ-UHFFFAOYSA-N 4-(7-chloro-6-phenyl-4-pyrrolidin-1-ylpteridin-2-yl)piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(N2CCN(CC2)C=O)=NC=1N1CCCC1 JYKRPHPHUQAIPZ-UHFFFAOYSA-N 0.000 description 1
- DAUCBPOTMUPLBF-UHFFFAOYSA-N 4-(7-chloro-6-phenyl-4-thiomorpholin-4-ylpteridin-2-yl)piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(N2CCN(CC2)C=O)=NC=1N1CCSCC1 DAUCBPOTMUPLBF-UHFFFAOYSA-N 0.000 description 1
- QHHLKOCFSWZNRA-UHFFFAOYSA-N 4-(7-morpholin-4-yl-6-phenyl-2-piperazin-1-ylpteridin-4-yl)-1,4-thiazinane 1-oxide Chemical compound O1CCN(CC1)C1=C(N=C2C(=NC(=NC2=N1)N1CCNCC1)N1CCS(CC1)=O)C1=CC=CC=C1 QHHLKOCFSWZNRA-UHFFFAOYSA-N 0.000 description 1
- BAUOJBQIZRQWRY-UHFFFAOYSA-N 4-[4-[benzyl(methyl)amino]-7-(dimethylamino)-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(N(C)C)=NC2=NC(N2CCN(CC2)C=O)=NC=1N(C)CC1=CC=CC=C1 BAUOJBQIZRQWRY-UHFFFAOYSA-N 0.000 description 1
- RQSVNURXHGGPTO-UHFFFAOYSA-N 4-[4-[benzyl(methyl)amino]-7-chloro-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound N=1C(N2CCN(CC2)C=O)=NC2=NC(Cl)=C(C=3C=CC=CC=3)N=C2C=1N(C)CC1=CC=CC=C1 RQSVNURXHGGPTO-UHFFFAOYSA-N 0.000 description 1
- CUNLKSCXVUNDRS-UHFFFAOYSA-N 4-[4-[benzyl(methyl)amino]-7-morpholin-4-yl-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound N=1C(N2CCN(CC2)C=O)=NC2=NC(N3CCOCC3)=C(C=3C=CC=CC=3)N=C2C=1N(C)CC1=CC=CC=C1 CUNLKSCXVUNDRS-UHFFFAOYSA-N 0.000 description 1
- MOBNUSJJGHFPFQ-UHFFFAOYSA-N 4-[6-phenyl-4,7-di(piperidin-1-yl)pteridin-2-yl]piperazine-1-carbaldehyde Chemical compound C1CN(C=O)CCN1C1=NC(N2CCCCC2)=C(N=C(C=2C=CC=CC=2)C(=N2)N3CCCCC3)C2=N1 MOBNUSJJGHFPFQ-UHFFFAOYSA-N 0.000 description 1
- YSNVSBCVZNWKGH-UHFFFAOYSA-N 4-[7-(1-oxo-1,4-thiazinan-4-yl)-6-phenyl-2-piperazin-1-ylpteridin-4-yl]-1,4-thiazinane 1-oxide Chemical compound O=S1CCN(CC1)C1=NC(=NC2=NC(=C(N=C12)C1=CC=CC=C1)N1CCS(CC1)=O)N1CCNCC1 YSNVSBCVZNWKGH-UHFFFAOYSA-N 0.000 description 1
- VSWBGFWNGWRKDM-UHFFFAOYSA-N 4-[7-chloro-4-(dimethylamino)-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound ClC1=C(N=C2C(=NC(=NC2=N1)N1CCN(CC1)C=O)N(C)C)C1=CC=CC=C1 VSWBGFWNGWRKDM-UHFFFAOYSA-N 0.000 description 1
- XXSIXQDELMYCTC-UHFFFAOYSA-N 4-n,4-n,7-n,7-n-tetramethyl-6-phenyl-2-piperazin-1-ylpteridine-4,7-diamine Chemical compound CN(C)C1=NC2=NC(N3CCNCC3)=NC(N(C)C)=C2N=C1C1=CC=CC=C1 XXSIXQDELMYCTC-UHFFFAOYSA-N 0.000 description 1
- CKISRHNGYULHGI-UHFFFAOYSA-N 4-n,7-n-dibenzyl-4-n,7-n-dimethyl-6-phenyl-2-piperazin-1-ylpteridine-4,7-diamine Chemical compound N=1C2=NC(N3CCNCC3)=NC(N(C)CC=3C=CC=CC=3)=C2N=C(C=2C=CC=CC=2)C=1N(C)CC1=CC=CC=C1 CKISRHNGYULHGI-UHFFFAOYSA-N 0.000 description 1
- YNYOHBFWUQAWQW-UHFFFAOYSA-N 4-pteridin-2-ylmorpholine Chemical compound C1COCCN1C1=NC=C(N=CC=N2)C2=N1 YNYOHBFWUQAWQW-UHFFFAOYSA-N 0.000 description 1
- ZONQLDOFIRSPFE-UHFFFAOYSA-N 4-pteridin-2-ylpiperazine-1-carbaldehyde Chemical class C1CN(C=O)CCN1C1=NC=C(N=CC=N2)C2=N1 ZONQLDOFIRSPFE-UHFFFAOYSA-N 0.000 description 1
- FMXXMLPFAFDKKZ-UHFFFAOYSA-N 6-phenyl-2-piperazin-1-yl-4,7-di(piperidin-1-yl)pteridine Chemical compound C1CCCCN1C1=NC2=NC(N3CCNCC3)=NC(N3CCCCC3)=C2N=C1C1=CC=CC=C1 FMXXMLPFAFDKKZ-UHFFFAOYSA-N 0.000 description 1
- LYHHTUKHEGOSDZ-UHFFFAOYSA-N 6-phenyl-2-piperazin-1-ylpteridine Chemical compound C1(=CC=CC=C1)C=1N=C2C=NC(=NC2=NC=1)N1CCNCC1 LYHHTUKHEGOSDZ-UHFFFAOYSA-N 0.000 description 1
- LLSMNKXJGLPMIW-UHFFFAOYSA-N 6-phenylpteridine Chemical compound C1=CC=CC=C1C1=CN=C(N=CN=C2)C2=N1 LLSMNKXJGLPMIW-UHFFFAOYSA-N 0.000 description 1
- LQIUVTVMTMIEMP-UHFFFAOYSA-N 7-morpholin-4-ylpteridin-2-amine Chemical compound NC1=NC2=NC(=CN=C2C=N1)N1CCOCC1 LQIUVTVMTMIEMP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- RBWMPAVUDZMFDB-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=CN=C2C(=NC(=NC2=N1)Cl)N1CCS(CC1)=O.C(C)O Chemical compound C(C1=CC=CC=C1)NC1=CN=C2C(=NC(=NC2=N1)Cl)N1CCS(CC1)=O.C(C)O RBWMPAVUDZMFDB-UHFFFAOYSA-N 0.000 description 1
- SQASYVUHUJVWGK-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=NC(=NC2=NC(=CN=C12)N1CCS(CC1)=O)Cl.O1CCOCC1 Chemical compound C(C1=CC=CC=C1)NC1=NC(=NC2=NC(=CN=C12)N1CCS(CC1)=O)Cl.O1CCOCC1 SQASYVUHUJVWGK-UHFFFAOYSA-N 0.000 description 1
- HQVYAFWHUPPZEP-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=NC(N(C2=NC=CN=C12)N1CCS(CC1)=O)N1CCNCC1 Chemical compound C(C1=CC=CC=C1)NC1=NC(N(C2=NC=CN=C12)N1CCS(CC1)=O)N1CCNCC1 HQVYAFWHUPPZEP-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- BKHOYPFGMWTOJL-UHFFFAOYSA-N ClC1=NC2=NC(=C(N=C2C(=N1)N1CCOCC1)C)N1CCOCC1.C(C)O Chemical compound ClC1=NC2=NC(=C(N=C2C(=N1)N1CCOCC1)C)N1CCOCC1.C(C)O BKHOYPFGMWTOJL-UHFFFAOYSA-N 0.000 description 1
- BXQDVFIUGUTETD-UHFFFAOYSA-N ClC1=NC2=NC(=CN=C2C(=N1)NCC1=CC=CC=C1)Cl.C(C)O Chemical compound ClC1=NC2=NC(=CN=C2C(=N1)NCC1=CC=CC=C1)Cl.C(C)O BXQDVFIUGUTETD-UHFFFAOYSA-N 0.000 description 1
- GFUBTAJUEDVKNV-UHFFFAOYSA-N ClC1=NC2=NC=CN=C2C(=N1)N1CCS(CC1)=O Chemical compound ClC1=NC2=NC=CN=C2C(=N1)N1CCS(CC1)=O GFUBTAJUEDVKNV-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000764773 Inna Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XMMFOLGAOPURJY-UHFFFAOYSA-N N-benzyl-4-(1-oxo-1,4-thiazinan-4-yl)-6-phenyl-2-piperazin-1-ylpteridin-7-amine Chemical compound C(C1=CC=CC=C1)NC1=C(N=C2C(=NC(=NC2=N1)N1CCNCC1)N1CCS(CC1)=O)C1=CC=CC=C1 XMMFOLGAOPURJY-UHFFFAOYSA-N 0.000 description 1
- SQYPTHMPHAUHSB-UHFFFAOYSA-N N-benzyl-N-methyl-7-morpholin-4-yl-6-phenyl-2-piperazin-1-ylpteridin-4-amine Chemical compound CN(C1=NC(=NC2=NC(=C(N=C12)C1=CC=CC=C1)N1CCOCC1)N1CCNCC1)CC1=CC=CC=C1 SQYPTHMPHAUHSB-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DXSGWJSZLBSYJQ-UHFFFAOYSA-N n-benzyl-2-chloro-7-(1-oxo-1,4-thiazinan-4-yl)pteridin-4-amine Chemical compound C=12N=CC(N3CCS(=O)CC3)=NC2=NC(Cl)=NC=1NCC1=CC=CC=C1 DXSGWJSZLBSYJQ-UHFFFAOYSA-N 0.000 description 1
- NNRYTKBMUOMWFL-UHFFFAOYSA-N n-benzyl-2-piperazin-1-yl-4-piperidin-1-ylpteridin-7-amine Chemical compound C=1C=CC=CC=1CNC(N=C1N=2)=CN=C1C(N1CCCCC1)=NC=2N1CCNCC1 NNRYTKBMUOMWFL-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012262 resinous product Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- ISPBABGJNLPGOY-UHFFFAOYSA-K zinc barium(2+) hydroxide sulfate Chemical compound [OH-].[Zn+2].[Ba+2].[O-]S([O-])(=O)=O ISPBABGJNLPGOY-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
' 82696'82696
Menetelmä valmistaa farmako.logisesti arvokkaita pteridiinejä -Förfarande för framstfil1ning av farmakologiskt värdefulla pteridinerMethod for preparing pharmacologically valuable pteridines -Förfarande för framstfil1ning av pharmacologiskt värdefulla pteridiner
Patenttijulkaisussa US-A-2.940.972 on jo kuvattu substituoituja pteridiinejä, joilla on arvokkaita farmakologisia ominaisuuksia, nimittäin sydäntä laajentava, sedätiivinen, antipyreetti-nen ja analgeettinen vaikutus.U.S. Pat. No. 2,940,972 already describes substituted pteridines having valuable pharmacological properties, namely cardiac dilating, sedative, antipyretic and analgesic activity.
Nyttemmin on havaittu, että uusilla yleiskaavan I mukaisilla pteridi inei1lä *7 ^ N 'V' N ^ *2It has now been found that with the new pteridines of the general formula I * 7 ^ N 'V' N ^ * 2
1 ID1 ID
:f: R4 ja niiden happoadditiosuoloi1 la on arvokkaita ominaisuuksia.: f: R4 and their acid addition salts have valuable properties.
Kun R2 tarkoittaa N-formyy1i-piperatsinoryhmää, ne ovat arvokkaita välituotteita valmistettaessa yleiskaavan I mukaisia pteridiinejä, joissa R2 on piperatsinoryhmä, ja niiden happo-additiosuoloja, erityisesti niiden fysiologisesti sopivia happoadditiosuoloja epäorgaanisten tai orgaanisten happojen kanssa. Näillä yhdisteillä on arvokkaita farmakologisia ominaisuuksia, erityisesti antitromboottinen vaikutus, metastaaseja estävä vaikutus ja tuumorien kasvua estävä vaikutus.When R2 represents an N-formyl-piperazino group, they are valuable intermediates in the preparation of pteridines of the general formula I in which R2 is a piperazino group and their acid addition salts, in particular their physiologically acceptable acid addition salts with inorganic or organic acids. These compounds have valuable pharmacological properties, in particular antithrombotic activity, anti-metastatic activity and anti-tumor growth activity.
Keksinnön kohteena on menetelmä valmistaa edellä olevan —: yleiskaavan I mukaisia yhdisteitä, jossa 2 82696 R2 on piperatsinoryhmä, R* on dialkyyliamino-, fenyylialkyyliamino-, N-a1kyyli-fenyyalkyy1i1iamino-, pyrrolidino-, piperidino-, morfolino-, tiomorfolino-, 1-oksidotiomorfolino-, tiatsolidino- tai 1-oksidotiatsolidinoryhmä, R6 on vetyatomi, alkyyli- tai fenyyliryhmä jaThe invention relates to a process for the preparation of compounds of general formula I above, in which 2 82696 R 2 is a piperazino group, R * is dialkylamino, phenylalkylamino, N-alkylphenylalkylamino, pyrrolidino, piperidino, morpholino, thiomorpholino, an oxidothiomorpholino, thiazolidino or 1-oxidothiazolidino group, R6 is a hydrogen atom, an alkyl or phenyl group and
Rt on alkyyliamino-, dialkyyliamino-, fenyy1ialkyy1iamino-, N-alkyy 1i-fenyy1i ai kyy 1i amino-, piperidino-, morfolino-, tiomorfolino-, 1-oksidotiomorfolino- tai piperatsinoryhmä, jolloin ryhmissä R4, Re ja R7 jokainen alkyyliosa voi sisältää 1 - 3 hiiliatomia ja samanaikaisesti ryhmien R4 ja R7 toinen tai kumpikin alkyyliryhmä, jossa on 2 tai 3 hiiliatomia, voi kulloinkin olla substituoitu hydroksiryhmällä 2 tai 3 asemassa.Rt is an alkylamino, dialkylamino, phenylalkylamino, N-alkyl-phenyl or amino, piperidino, morpholino, thiomorpholino, 1-oxidothiomorpholino or piperazino group, wherein each alkyl moiety in R4, Re and R7 may contain 1 to 3 carbon atoms and, at the same time, one or both alkyl groups of the groups R4 and R7 having 2 or 3 carbon atoms may in each case be substituted by a hydroxy group in the 2 or 3 position.
Esillä olevan keksinnön kohteena ovat siten välituotteiksi sopivat edellä olevan yleiskaavan I mukaiset uudet 2-(N-formyyli-piperatsino)-pteridiinit ja niiden happoadditiosuolat ja edellä olevan yleiskaavan I mukaisten uusien 2-piperatsino-pteridiinien, niiden happoadditiosuolojen, erityisesti niiden fysiologisesti sopivien happoadditiosuolojen epäorgaanisten tai orgaanisen happojen kanssa.The present invention therefore relates to novel 2- (N-formylpiperazino) pteridines of the above general formula I and their acid addition salts which are suitable as intermediates and to novel 2-piperazino pteridines of the above general formula I, their acid addition salts, in particular their physiologically acceptable acid addition salts. or with organic acids.
Ryhmien R4, Re ja Rt määritelmässä mainittuina merkityksinä tulevat kysymykseen erityisesti seuraavat: R4 on dimetyyliamino-, dietyy1iamino-, di-n-propyy1iamino-, di-isopropyyliamino-, N-metyyli-etyyliamino-, N-etyyli-n-propyyliamino-, bentsyyliamino-, N-metyy1i-bentsyy1iamino-, N-etyy1i-bentsyy1iamino-, N-n-propyy1i-bentsyy1iamino-, 1- fenyylietyyliamino-, 2-fenyylietyyliamino-, 3-fenyyli-propyyliamino-, N-metyy1i-1-fenyylietyyliamino-, N-etyyli- 2- fenyylietyyliamino-, N-etyy1i-3-fenyy1ipropyy1i- 3 82696 amino-, bis(2-hydroksiet yyli)-amino-, bis(2-hydroksi-n-propyyli )-amino-, bis(3-hydroksi-n-propyy1i)-amino-, N —(2 — hydroksietyyli )-2-hydroksi~n~propyyliamino-, N-metyyli-2-hydroksietyyliamino-, N-etyyli-2-hyd roksi etyyiiamino-, Ni-metyyli-2-hydroksi-n-propyyliamino-, N-isopropyyli- 2- hydroksi-etyyliamino-, N-(2-hydroksietyyli)-bentsyyliamino-, pyrrolidino-, piperidino-, morfolino-, tiomorfo 1lno-, 1-oksidotiomorfolino-, tiatsolidino- tai 1-oksidotiatsolidino-ryhmä, K on vetyatomi, metyyli-, etyyli-, n-propyyli-, isopropyyli-6 tai f e n y y 1 l r y Inna ja H on metyy1lamino-, etyyiiamino-, n-propyy1iamino-, iso-propyyliamino-, dimetyyliamino-, dietyyliamino-, di-n-propyyliamino-, di-isopropyyliamino-, N-metyyli-etyyliamino-, N-etyy1i-N-prupyy 1 iamino-, bentsyyliamino-, N-metyyli-bentsyyliaininu - , N-etyyli-bentsyyliamino-, N-n-propyyli-bentsyyliammo-, 1-tenyylietyyliamino-, 2-fenyylietyyliamino-, 3- fenyylipropyyiiamino-, N-metyyli-l-fenyylietyyliamino-, N-etyyli-2-fenyylietyyiiamino-, N-etyyli-3- . fenyylipropyyiiarnino-, 2-hydroksietyyiiamino-, 2-hydroksi- n-propyyliamino-, 3-hydroksi-n-propyyliamino, 2-hydroksi-isopropyyliamino-, bis(2-hyroksietyyli)-amino-, bis(2-hydroksi-η-ρropyy1i)-amino-, bis(3-hydroksi-n-propyyli)-.· amino-, N-(2-hydroksietyy1i)-2-hydroksi-n-propyyliamino-, N-metyy1i-2-hydroksietyyliamino-, N-etyyli-2-hydroksi-etyyiiamino-, N-metyy1i-2-hydroksi-n-propyyliamino-, N-isopropyyli-2-hydroksi-etyyliamino, N-(2-hydroksi-etyyli )-bentsyy1iamino-, piperidino-, morfolino-, tiomor-folino-, 1-oksidotiomorfolino-, tiatsolidino-, 1-oksido-tiatsolidino- tai piperatsinoryhmä.In the definition of the groups R4, Re and Rt, the meanings given are in particular the following: R4 is dimethylamino, diethylamino, di-n-propylamino, diisopropylamino, N-methylethylamino, N-ethyl-n-propylamino, benzylamino, N-methyl-benzylamino, N-ethyl-benzylamino, Nn-propyl-benzylamino, 1-phenylethylamino, 2-phenylethylamino, 3-phenylpropylamino, N-methyl-1-phenylethyl N-ethyl-2-phenylethylamino, N-ethyl-3-phenylpropyl-3,82696 amino, bis (2-hydroxyethyl) amino, bis (2-hydroxy-n-propyl) amino, bis (3 -hydroxy-n-propyl) amino, N- (2-hydroxyethyl) -2-hydroxy-n-propylamino, N-methyl-2-hydroxyethylamino, N-ethyl-2-hydroxyethylamino, N- methyl 2-hydroxy-n-propylamino, N-isopropyl-2-hydroxyethylamino, N- (2-hydroxyethyl) benzylamino, pyrrolidino, piperidino, morpholino, thiomorpholino, 1-oxidothiomorpholino- , a thiazolidino or 1-oxidothiazolidino group, K is hydrogen, methyl, ethyl, n-propyl, isopropyl-6 or phenyl Inna and H is methylamino, ethylamino, n-propylamino, isopropylamino, dimethylamino, diethylamino, di-n -propylamino, diisopropylamino, N-methylethylamino, N-ethyl-N-propylamino, benzylamino, N-methylbenzylamino, N-ethylbenzylamino, Nn-propylbenzylamino , 1-phenylethylamino, 2-phenylethylamino, 3-phenylpropylamino, N-methyl-1-phenylethylamino, N-ethyl-2-phenylethylamino, N-ethyl-3-. phenylpropylamino, 2-hydroxyethylamino, 2-hydroxy-n-propylamino, 3-hydroxy-n-propylamino, 2-hydroxyisopropylamino, bis (2-hydroxyethyl) amino, bis (2-hydroxy-η- ρropyl) amino, bis (3-hydroxy-n-propyl) -, amino, N- (2-hydroxyethyl) -2-hydroxy-n-propylamino, N-methyl-2-hydroxyethylamino, N- ethyl 2-hydroxyethylamino, N-methyl-2-hydroxy-n-propylamino, N-isopropyl-2-hydroxyethylamino, N- (2-hydroxyethyl) benzylamino, piperidino, morpholino- , a thiomorpholino, 1-oxidothiomorpholino, thiazolidino, 1-oxido-thiazolidino or piperazino group.
Parhaina pidettyjä edellä olevan yleiskaavan I mukaisia yndisteitä ovat ne, joissa R2 on pipo ra tojnoryhmä, 4 82696 R^ on dimetyyliamino-, N-metyyli-2-hydroksietyyliamino-, bis (2-hydroksietyyli)-amino-, bentsyyliamino-, N-metyyli-bentsyyliamino-, pyrrolidino-, piperidino-, morfolino-, Liomorfolino-, 1-oksidotiomorfo1ino-, tiatsolidino- tai 1-oksidotiatsilid.inoryhmä, R on vetyatomi, metyyli- tai fenyyliryhmä ja R^ on dimetyyliamino-, N-metyyli-2-hydroksietyyliamino-, bentsyyliamino-, N-metyy1i-bentsyy1iamino-, piperidino-, morfolino-, tiomurf o 1ino-, 1-oksidotiomorfolino- tai piperatsinoryhmä, ja niiden happoadditiosuolat, erityisesti niiden f y s iolocj l ees t j sopivat happoadditiosuolat.Preferred compounds of the above general formula I are those in which R 2 is a piperino group, 4 82696 R 1 is dimethylamino, N-methyl-2-hydroxyethylamino, bis (2-hydroxyethyl) amino, benzylamino, N- methylbenzylamino, pyrrolidino, piperidino, morpholino, Liomorpholino, 1-oxidothiomorpholino, thiazolidino or 1-oxidothiazilidino group, R is a hydrogen atom, a methyl or phenyl group and R 1 is dimethylamino, N-methyl 2-Hydroxyethylamino, benzylamino, N-methylbenzylamino, piperidino, morpholino, thiomurfino, 1-oxidothiomorpholino or piperazino group, and their acid addition salts, in particular their acid addition salts with suitable acid additions.
Erityisen hyvinä pidetään kuitenkin edellä olevan yleiskaavan 1 mukaisia yhdisteitä, joissa ja tarkoittavat samaa kuin edellä, R^ on pyrrolidino-, piperidino-, morfolino-, tiomorfolino-, 1-oksidotiomorfolino- tai N-metyyli-2-hydroksietyyliaminoryhmä ja * R^ on dimetyyliamino-, bentsyyliamino, N-metyyli- bentsyy1iamino-, morfolino-, tiomorfolino- tai 1-oksidotiomorfolinoryhmä.However, compounds of general formula 1 above in which and have the same meaning as above are particularly preferred, R 1 is a pyrrolidino, piperidino, morpholino, thiomorpholino, 1-oxidothiomorpholino or N-methyl-2-hydroxyethylamino group and * R 1 is a dimethylamino, benzylamino, N-methylbenzylamino, morpholino, thiomorpholino or 1-oxidothiomorpholino group.
Keksinnön mukaisesti saadaan uudet yhdisteet seuraavilla menetelmillä: a) Yleiskaavan II mukainen yhdiste Z7 N ^ N'^ Z2 1 T 1 N >UI)According to the invention, the novel compounds are obtained by the following methods: a) Compound of general formula II Z7 N 1 N 2 N 2
R6 N TR6 N T
;·; % 5 82696 jossa R ^ ja R^ tarkoittavat samaa kuin edellä, toinen ryhmistä Z ^ tai Z ^ on nukleofiilisesti vaihdettavissa oleva ryhmä, kuten halogeeniatomi, esimerkiksi kloori-tai bromiatomi ja toinen ryhmistä Z^ tai tarkoittaa samaa kuin tai R^ edellä tai, mikäli valmistetaan yleiskaavan I mukainen yhdiste, jossa ryhmät R^ ja R^ tarkoittavat samaa, myös nukleofiilisesti vaihdettavissa oleva ryhmä, kuten halogeeni-atomi, esimerkiksi kloori- tai bromiatomi, saatetaan reagoimaan yleiskaavan III mukaisen amiinin kanssa H - X (III) jossa X tarkoittaa samaa kuin R^ tai R^ edellä tai hydrolyyttisesti poislohkais tavissa olevalla suojaryhmällä suojattu piperat-sinoryhmä, ja tarvittaessa sen jälkeen lohkaistaan käytetty suojaryhmä pois.; ·; % 5 82696 wherein R 1 and R 2 are as defined above, one of Z 1 or Z 2 is a nucleophilically exchangeable group such as a halogen atom, for example a chlorine or bromine atom and the other of Z 1 or the same is as or R 1 above or if a compound of general formula I is prepared in which the groups R 1 and R 2 represent the same, a nucleophilically exchangeable group such as a halogen atom, for example a chlorine or bromine atom, is reacted with an amine of general formula III H - X (III) in which X is the same as R1 or R1 above or a piperazine group protected by a hydrolytically cleavable protecting group, and, if necessary, the cleaved protecting group is then cleaved off.
Reaktio suoritetaan tarkoituksenmukaisesti liuottimessa, kuten tetra hydrufuraanissa, dioksaanissa, bentseenissä, tolueemssa, d j me t. y y 1 i su 1 f ok s i d issa tai dimetyyliglykoli-: eetterissä lämpötiloissa välillä 0 ja 150°C, parhaiten • huoneen lämpötilan ja käytetyn liuottimen kiehumislämpötilan i välillä, tai sulatteessa. Tällöin voi olla edullista käyttää ; happoa sitovaa ainetta, kuten natriumkarbonaattia, tri- - etyyliamiinia tai pyridiiniä.The reaction is conveniently carried out in a solvent such as tetrahydrofuran, dioxane, benzene, toluene, ethylene or dimethyl glycol: ether at temperatures between 0 and 150 ° C, preferably at room temperature and the boiling point of the solvent used. between, or in the melt. In this case, it may be advantageous to use; an acid scavenger such as sodium carbonate, triethylamine or pyridine.
Mahdollisesti tarvittava käytetyn suojaryhmän poislohkai-seminen tapahtuu joko hydrolyyttisesti hapon, kuten suolahapon tai rikkihapon läsnäollessa tai emäksen, kuten natriumhyd-roksidin tai kaiiumhydroksidin läsnäollessa parhaiten vesipitoisessa liuottimessa, kuten metanoli/vedessä, etanoli/ '! vedessä tai dioksaani/vedessä lämpötiloissa, jotka ulottuvat aina käytetyn liuottimen kiehumisiämpötilaan asti. Käytetyn suojaryhmän po i s 1 uhka i Heininen voi tapahtua myös samanai-*·· kaisesti reaktion aikana käyttämällä ylimäärää yleiskaavan 6 82696 III mukaista käytettyä amiinia.Any necessary cleavage of the protecting group used takes place either hydrolytically in the presence of an acid such as hydrochloric acid or sulfuric acid or in the presence of a base such as sodium hydroxide or potassium hydroxide, preferably in an aqueous solvent such as methanol / water, ethanol / '! in water or dioxane / water at temperatures up to the boiling point of the solvent used. The threat of the protecting group used can also occur simultaneously during the reaction by using an excess of the amine of the general formula 6 82696 III used.
b) Sellaisten yleiskaavan I mukaisten yhdisteiden valmistamiseksi, joissa R on 1-oksidotiomorfolino- tai 1-oksido-tiatsolidinoryhmä ja/tai on 1-oksidotiomorfolinoryhmä:b) For the preparation of compounds of general formula I in which R is a 1-oxidothiomorpholino or 1-oxidothiazolidino group and / or is a 1-oxidothiomorpholino group:
Hapetetaan yleiskaavan IV mukainen yhdiste R * N N R2 7 γ Y Ύ .uv) S6 1 R ' 4 jossa R^ ja Rg tarkoittavat samaa kuin edellä, ' ja R^' tarkoittavat samaa kuin R^ ja R^ edellä, jolloin kuitenkin ainakin toisen ryhmistä R^' tai R^ ' on oltava tiomorfolinoryhmä tai R 1 ryhmännyös tiatsolidinoryhmä.Oxidation of a compound of general formula IV R * NN R2 7 γ Y Ύ .uv) S6 1 R '4 wherein R1 and R8 have the same meaning as above,' and R4 'have the same meaning as R1 and R4 above, with at least one of the groups R 1 'or R 2' must be a thiomorpholino group or an R 1 group and a thiazolidino group.
• Hapettaminen suoritetaan parhaiten liuottimessa tai liuotin- : seoksessa, esimerkiksi vedessä, vesi/pyridiinissä, asetonissa, jääetikassa, mety1eenikloridissa, dioksaanissa, laimeassa rikkihapossa tai trifluorietikkahapossa, käytetystä hapet-·. timesta riippuen tarkoituksenmukaisesti lämpötiloissa välillä ϋ ja 150°C.• The oxidation is best carried out in a solvent or solvent mixture, for example water, water / pyridine, acetone, glacial acetic acid, methylene chloride, dioxane, dilute sulfuric acid or trifluoroacetic acid. depending on the temperature at temperatures between ϋ and 150 ° C.
Hapettaminen suoritetaan parhaiten käytetyn hapettimen ekvivalentilla, esimerkiksi vetyperoksidilla jääetikassa, trifluorietikkanapossa tai muurahaishapossa 0 - 20°C:ssa tai asetonissa 0 - 60°C:ssa, perhapolla, kuten permuurahais-hapolla jääetikassa tai trifluorietikkahapossa 0 - 50°C:Ssa .* tai m-klooriperbentsoehapolla metyleenikloridissa tai *, kloroformissa 0 - 60°C:ssa, natirummetaperjodaatilla diok saanissa tai etanolissa 80 - 100°C:ssa, bromilla jääetikassa • · 7 82696 tai vesipitoisella etikkahapolla, N-bromisukkinimidillä etanolissa, jodibentsodikloridilla vesipitoisessa pyridiinissä ϋ - 50°C:ssa, typpihapolla jääetikassa 0 - 20°C:ssa ja bromihapolla jääetikassa tai asetonissa 0 - 20°C:ssa.The oxidation is carried out with an equivalent of the most preferred oxidant, for example hydrogen peroxide in glacial acetic acid, trifluoroacetic acid or formic acid at 0 to 20 ° C or acetone at 0 to 60 ° C, peracid such as formic acid in glacial acetic acid or trifluoroacetic acid at 0 to 50 ° C. * Or m-chloroperbenzoic acid in methylene chloride or *, chloroform at 0-60 ° C, sodium metaperiodate in dioxane or ethanol at 80-100 ° C, bromine in glacial acetic acid • · 7 82696 or aqueous acetic acid, N-bromosuccinimide in 50 ml ° C, nitric acid in glacial acetic acid at 0-20 ° C and bromic acid in glacial acetic acid or acetone at 0-20 ° C.
Keksinnön mukaisesti saadut yhdisteet voidaan muuntaa happoadditiosuoloikseen, erityisesti fysiologisesti sopiviksi suoloikseen epäorgaanisten tai orgaanisten happojen kanssa. Happoina tulevat tällöin kysymykseen esimerkiksi suolahappo, bromivetyhappo , rikkihappo, fosforihappo, maitohappo, sitruunahappo, viinihappo, meripihkahappo, maleiinihappo tai fumaarihappo.The compounds obtained according to the invention can be converted into their acid addition salts, in particular into their physiologically acceptable salts with inorganic or organic acids. Suitable acids are, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, lactic acid, citric acid, tartaric acid, succinic acid, maleic acid or fumaric acid.
Lähtöaineena käytetyt yleiskaavojen II - IV mukaiset yhdisteet ovat suurimmalta osalta tunnettuja tai ne saadaan patenttijulkaisussa US-A-2.940.972 kuvatulla menetelmällä (kts.The compounds of the general formulas II to IV used as starting materials are for the most part known or are obtained by the method described in U.S. Pat. No. 2,940,972 (see
esimerkit A - D).examples A to D).
Edellä jo mainittiin, että uusilla yleiskaavan I mukaisilla yhdisteillä, joissa R2 on piperatsinoryhmä, ja niiden happoadditiosuo1 o11 la , erityisesti niiden fysiologisesti *· sopivilla happoadditiosuoloilla epäorgaanisten tai orgaanisten happojen kanssa, on arvokkaita farmakologisia ominaisuuksia, erityisesti kuitenkin antitromboottinen ja metastaaseja » estävä vaikutus ja fos f od ies terassia estävä vaikutus ja tuumorien kasvua estävä vaikutus.It has already been mentioned above that the novel compounds of the general formula I in which R2 is a piperazino group and their acid addition salts, in particular their physiologically acceptable acid addition salts with inorganic or organic acids, have valuable pharmacological properties, in particular antithrombotic and anti-metastatic activity and f od ies anti-terrace effect and anti-tumor growth effect.
Seuraavalla tavalla tutkittiin Poch'in et ai. (kts. Na-yinyn-Schmiedebergs Arch. Pharmak. 268, 272-291 (1971) tietojen perusteella esimerkiksi seuraavien yhdisteiden tuumorisolujen ja ihmisen trombosyyttien fosfodiesteraasia (PDE) estävä vaikutus: k 1 k 1/ A = 4,7-dirnor fol ino-6-f enyyli-2-pipera tsino-pteridiini , • · • · « • · 8 82696 B = ή-morfoiino-7-(1-oksidotiomorfolino)-2-piperatsino- 6-fenyyli-pteridiini, C r 7-bentsyyliamino-6-fenyyli-2-piperatsino-4-tiomor-folino-pteridiini, D = 7-dimetyyliamino-6-fenyy1i-2-piperatsino-4-pyrro-lidino-pteridnni ja E = 7-bentsyyliamino-4-(N-metyyli-2'-hydroksietyyliamino)- 2-piperat. s ino-μ t eridiini a) Entsyymin talteenotto;In the following manner, the study of Poch et al. (See Na-yinyn-Schmiedebergs Arch. Pharmak. 268, 272-291 (1971)), for example, the phosphodiesterase (PDE) inhibitory activity of the following compounds on tumor cells and human platelets: k 1 k 1 / A = 4,7-dirnor fol ino -6-phenyl-2-piperazino-pteridine, • · • · «• · 8 82696 B = ή-morpholino-7- (1-oxidothiomorpholino) -2-piperazino-6-phenyl-pteridine, C r 7- benzylamino-6-phenyl-2-piperazino-4-thiomorpholino-pteridine, D = 7-dimethylamino-6-phenyl-2-piperazino-4-pyrrolidinopteridine and E = 7-benzylamino-4- (N -methyl-2'-hydroxyethylamino) -2-piperazine-μ t eridine (a) Enzyme recovery;
Fosfodiesteraasi saatiin hiirten B16 melanomakudoksesta sentrifugoimalla kudoshomogenaattia 5.000 x g (15 minuuttia, 4°C). Kudoksen homogenisointi suoritettiin toistuvasti pakastamalla ja sulattamalla ja homogenisoimalla Potter-Elvehjem-menetelmällä tai ultraäänellä. PDE-pitoinen homo-genaatin supernatantti jaettiin osiin ja syväpakastettiin -25°C:ssa.Phosphodiesterase was obtained from melanoma tissue of mouse B16 by centrifugation of tissue homogenate at 5,000 x g (15 minutes, 4 ° C). Tissue homogenization was performed repeatedly by freezing and thawing and homogenization by the Potter-Elvehjem method or ultrasound. The PDE-containing homogenate supernatant was aliquoted and deep-frozen at -25 ° C.
Fosfodiesteraasi saatiin ihmisen trombosyyteistä samalla 1 tavalla.Phosphodiesterase was obtained from human platelets in the same 1 manner.
* b) PDE-estovaikutuksen määrittäminen (PDE-assay): 4 » ^ Tutkittavien aineiden PDE-estovaikutus määritettiin käyt tämällä substraattina 1 jumol/l ^H-cAMP:ta. POE-estovaikutus saatiin mittaamalla käytetyn ^H-cAMP-substraatin hajoaminen ^H-AMP:ksi verrattuna kontrolliin, jossa ei ollut tutkittavaa ainetta. Muodostunut ^H-AMP erotettiin jäljelle jääneestä " ^H-cAMP : sta sinkkisulf aatti-bariumhydroksidi-saostuksen . . avulla.* b) Determination of the PDE inhibitory effect (PDE assay): The PDE inhibitory effect of the test substances was determined using 1 [mu] mol / l H-cAMP as substrate. The POE inhibitory effect was obtained by measuring the degradation of the β-H-cAMP substrate used to β-H-AMP compared to a control without test substance. The formed 1 H-AMP was separated from the remaining "H-cAMP" by zinc sulfate-barium hydroxide precipitation.
• 0 • · 4 1 li • · ' · oli korisen t raa t io , joka esti PDE-aktiivisuutta 50 λ, laskettiin lineaarisen regressioanalyysin avulla.• 0 • · 4 1 li • · '· was the basket t i ra tion that inhibited PDE activity by 50 λ was calculated by linear regression analysis.
9 826969,82696
Aine PDE-estovaikutus (IC^g, umol/1)PDE inhibitory effect of the substance (IC 2 g, μmol / l)
Trombosyytit B16-tuumorisolut A 0,54 4,3 B 2,2 3,1 C 0,5 0,096 D 3,6 0,78 E 3,7 8,3Platelets B16 tumor cells A 0.54 4.3 B 2.2 3.1 C 0.5 0.096 D 3.6 0.78 E 3.7 8.3
Akuutti toksisuus:Acute toxicity:
Tutkittavien aineiden orientoiva akuutti toksisuus määritettiin suuntaa-untavasti yhden yksittäisen annoksen oraalin antamisen jälkeen 10 hiiren ryhmillä (tarkkailuaika: 14 päivää): . Aine Orientoiva akuutti toksisuus « · A £ 250 mg (5 eläimestä kuoli 0) C s 250 mg (5 eläimestä kuoli 0) .·· D & 250 mg (5 eläimestä kuoli 0) E S 250 mg (5 eläimestä kuoli 0)The indicative acute toxicity of the test substances was determined approximately after a single oral dose in groups of 10 mice (observation period: 14 days):. Substance Indicative acute toxicity «· A £ 250 mg (5 animals died 0) C s 250 mg (5 animals died 0) ·· D & 250 mg (5 animals died 0) E S 250 mg (5 animals died 0)
Keksinnön mukaisesti valmistetut uudet yleiskaavan I mukaiset yhdisteet, joissa on piperatsinoryhmä, ja niiden fysiologisesti sopivat happoadditiosuolat sopivat edellä mainittujen farmakologisten ominaisuuksiensa vuoksi trombo-‘l embolisten sairauksien, kuten sydäninfarktin, aivoinfarktin, .!.* nk. transienttien iskeemisten kohtauksien, Amaurosis **\ fugax-taudin profylaksiaan, arterioskleroosin profylaksiaan, metastaasien profylaksiaan ja tuumorin kasvun estämiseen.The novel compounds of the general formula I having a piperazino group according to the invention and their physiologically acceptable acid addition salts are suitable for the ischemic sites of thrombo-1 embolic diseases such as myocardial infarction, cerebral infarction, so-called transient ischemic diseases due to their above-mentioned pharmacological properties. prophylaxis of fugax disease, prophylaxis of arteriosclerosis, prophylaxis of metastases and inhibition of tumor growth.
• ··· ·· · t · 10 82696• ··· ·· · t · 10 82696
Vastaavan vaikutuksen aikaansaamiseen tarvittava annostus on tarkoituksenmukaisesti 2-4 kertaa päivässä 0,1 -4 mg/painokilo, parhaiten 0,2 - 3 mg/painoki1o. Tätä varten voidaan keksinnön mukaisesti valmistetut yleiskaavan I yhdisteet, joissa on piperatsinoryhmä, sekä niiden fysiologisesti sopivat happoadditiosuolat epäorgaanisten tai orgaanisten happojen kanssa, mahdollisesti yhdistelmänä muiden tehoaineiden kanssa, työstää yhdessä yhden tai useamman inertin tavanomaisen kantajan ja/tai laimennusaineen, esimerkiksi maissitärkkelyksen, maitosokerin, ruokosokerin, mikrokiteisen selluloosan, magnesiumstearaatin, polyvinyyli-pyrro 1idonin, sitruunahapon, viinihapon, veden, vesi/etanolin, vesi/glyseriinin, vesi/sorbiitin, ei-ionillisten tensidien, kuten esimerkiksi polyoksietyleeni-rasvahappoesterin, vesi-polyetyleenig1yko1 in, propyleeniglykolin, setyyli-stearyylialkoholin, karboksimetyyliselluloosan tai rasvapitoisten aineiden, kuten kovarasvan tai niiden sopivien seosten kanssa työstää tavanomaisiksi galeenisiksi valmiste-muodoiksi, kuten tableteiksi, lääkerakeiksi, kapseleiksi, jauheiksi, suspensioiksi, tipoiksi, ampulleiksi, mehuiksi tai puikoiksi.The dosage required to produce a similar effect is suitably 2-4 times a day 0.1 to 4 mg / kg body weight, preferably 0.2 to 3 mg / kg body weight. To this end, the compounds of the general formula I prepared according to the invention having a piperazino group and their physiologically acceptable acid addition salts with inorganic or organic acids, optionally in combination with other active ingredients, can be processed together with one or more inert conventional carriers and / or diluents, e.g. corn starch, lactose, , microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerin, water / sorbitol, nonionic surfactants such as polyoxyethylene fatty acid ester, water polyethylene glycol, ethylene glycol, propylene, propylene , carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof can be processed into conventional galenic formulations such as tablets, granules, capsules, powders, suspensions, drops, ampoules and into juices or sticks.
««
Seuraavat esimerkit selventävät keksintöä lähemmin:The following examples further illustrate the invention:
Esimerkki AExample A
V 2.7-dikloori-4-morfolino-pteridiini 7,03 g (0,03 moolia) 2,4,7-1rikloori-pteridiiniä liuotetaan 100 mlsaan kloroformia ja lisäten 5°C:ssa liuos, jossa on 3,0 g (0,03 moolia) kaliumvetykarbonaattia 50 mlsssa '**; vettä. Sen jälkeen lisätään tipottain 2,62 g (0,03 moolia) morfoliinia 50 mlsssa kloroformia ja sekoitetaan 45 minuuttia • · huoneen lämpötilassa. Tämän jälkeen orgaaninen faasi ero- ··· tetaan, kuivataan natriumsulfaatilla ja haihdutetaan tyhjössä.V 2,7-Dichloro-4-morpholino-pteridine 7.03 g (0.03 mol) of 2,4,7-trichloropteridine are dissolved in 100 ml of chloroform and a solution of 3.0 g (0 .03 moles) of potassium bicarbonate in 50 ml '**; of water. 2.62 g (0.03 mol) of morpholine in 50 ml of chloroform are then added dropwise and the mixture is stirred for 45 minutes at room temperature. The organic phase is then separated, dried over sodium sulfate and evaporated in vacuo.
82696 Jäännös kiteytetään uudelleen etanolista.82696 The residue is recrystallized from ethanol.
Saanto: 7,4 g (86 % teoreettisesta),Yield: 7.4 g (86% of theory),
Sulamispiste: 187-188°CMelting point: 187-188 ° C
Analogisesti esimerkin A kanssa saadaan seuraajat yhdisteet: 2.7- dikloori-4-piperidino-pteridiini Saanto: 67 % teoreettisesta,In analogy to Example A, the following compounds are obtained: 2.7-dichloro-4-piperidino-pteridine Yield: 67% of theory,
Sulamispiste: 152-154°C (etanoli) 2.7- dikloori-4-bentsyyliamino-pteridiini Saanto: 75 % teoreettisesta,Melting point: 152-154 ° C (ethanol) 2,7-dichloro-4-benzylaminopteridine Yield: 75% of theory,
Sulamispiste: 150-152°C (metanoli) 2.7- dikloon-4-(l-oksidotiomorfolino)-pteridiini Saanto: 65 % teoreettisesta,Melting point: 150-152 ° C (methanol) 2.7-dichlorone-4- (1-oxidothiomorpholino) -pteridine Yield: 65% of theory,
Sulamispiste: 230-235°CMelting point: 230-235 ° C
2.7- dikloori-4-(N-metyyli-2'-hydroksietyyliamino)-pteridiini Saanto: 74 % teoreettisesta,2,7-dichloro-4- (N-methyl-2'-hydroxyethylamino) -pteridine Yield: 74% of theory,
Sulamispiste: 178-180°CMelting point: 178-180 ° C
.·. 2,7-dikloori-4-dietanoliamino-pteridiini » » " Saanto: 71 % teoreettisesta, * Sulamispiste: 173-174°C (etanoli) : : 2,7-dikloori-6-metyyli-7-morfolino-pteridiini. ·. 2,7-Dichloro-4-diethanolamino-pteridine »» "Yield: 71% of theory, * Melting point: 173-174 ° C (ethanol):: 2,7-dichloro-6-methyl-7-morpholino-pteridine
Saanto: 73 % teoreettisesta,Yield: 73% of theory,
Sulamispiste: 230-232°C (etanoli)Melting point: 230-232 ° C (ethanol)
Esimerkki BExample B
*· 2,7-dikloori-6-fenyyli-4-tiomorfolino-pteridiini 35,5 g (0,114 moolia) 2,4,7-1rik1oori-6-fenyy1i-pteridiiniä •\ liuotetaan 500 ml:aan asetonia ja lisätään 11,5 g (0,13 moolia) na tr iumvetykarbonaattia 120 ml : ssa vettä. Sen • · - 1 « 12 82696 jälkeen lisätään liuos, jossa on 11,8 g (0,114 moolia) tiomorfoliinia, ja sekoitetaan vielä 45 minuuttia huoneen lämpötilassa. Tämä liuos kaadetaan 2 litraan vettä, saatu sakka otetaan talteen ja kiteytetään uudelleen etyleeni-kloridista.* · 2,7-Dichloro-6-phenyl-4-thiomorpholino-pteridine 35.5 g (0.114 mol) of 2,4,7-trichloro-6-phenyl-pteridine are dissolved in 500 ml of acetone and 11 ml of acetone are added. 5 g (0.13 mol) of sodium hydrogen carbonate in 120 ml of water. After that, a solution of 11.8 g (0.114 mol) of thiomorpholine is added and the mixture is stirred for a further 45 minutes at room temperature. This solution is poured into 2 liters of water, the precipitate obtained is collected and recrystallized from ethylene chloride.
Saanto: 36 g (84 % teoreettisesta),Yield: 36 g (84% of theory),
Sulamispiste: 225-227°CMelting point: 225-227 ° C
Esimerkin B kanssa analogisesti saadaan seuraavat yhdisteet: 2.7- dikloori-4-(l-oksidotiomorfolino)-6-fenyyli-pteridiini Saanto: 88 % teoreettisesta,In analogy to Example B, the following compounds are obtained: 2.7-dichloro-4- (1-oxidothiomorpholino) -6-phenyl-pteridine Yield: 88% of theory,
Sulamispiste: 222-224°CMelting point: 222-224 ° C
2.7- dikloori-4-morfolino-6-fenyyli-pteridiini Saanto: 78 % teoreettisesta,2,7-dichloro-4-morpholino-6-phenyl-pteridine Yield: 78% of theory,
Sulamispiste: 198-201°CMelting point: 198-201 ° C
2.7- dikloori-6-fenyyli-4-piperidino-pteridiini Saanto: 69 ?ό teoreettisesta,2,7-Dichloro-6-phenyl-4-piperidino-pteridine Yield: 69% of theoretical,
Sulamispiste: 168-170°C (etikkahappoesteri ) *: 2,7-dikloori-4-dimetyyliamino-6-fenyyli-pteridiini *; Saanto: 77 % teoreettisesta,Melting point: 168-170 ° C (acetic acid ester) *: 2,7-dichloro-4-dimethylamino-6-phenyl-pteridine *; Yield: 77% of theory,
Sulamispiste: 236-238°C (etyleenikloridi) 2.7- dikloori-4-(N-metyyli-2'-hydroksietyyliamino)-6-fenyyli-pteridiiniMelting point: 236-238 ° C (ethylene chloride) 2,7-dichloro-4- (N-methyl-2'-hydroxyethylamino) -6-phenyl-pteridine
Saanto: 76 % teoreettisesta,Yield: 76% of theory,
Sulamispiste: 162-164°C (etanoli) 2.7- dikloori-4-(N-bentsyyli-metyyliamino)-6-fenyyli- :1 pteridiiniMelting point: 162-164 ° C (ethanol) 2,7-dichloro-4- (N-benzylmethylamino) -6-phenyl-: 1 pteridine
Saanto: 59 % teoreettisesta,Yield: 59% of theory,
Sulamispiste: 141-143°C (etanoli/dioksaani) i · • · * « · 15 82696 2.7- dikloori-6-fenyyli-4-pyrrolidino-pteridiini Saanto: 81 % teoreettisesta,Melting point: 141-143 ° C (ethanol / dioxane) i · • · * «· 15 82696 2.7-dichloro-6-phenyl-4-pyrrolidino-pteridine Yield: 81% of theory,
Sulamispiste: 199-200°C (etikkahappoesteri) 2.7- dikloori-6-fenyyli-4-tiatsolidino-pteridiini Saanto: 82 % teoreettisesta,Melting point: 199-200 ° C (acetic acid ester) 2,7-dichloro-6-phenyl-4-thiazolidino-pteridine Yield: 82% of theory,
Sulamispiste: 169-171°C (etikkahappoesteri)Melting point: 169-171 ° C (acetic acid ester)
Esimerkki CExample C
7-kloori-2-(N-formyylipipreatsino)-6-fenyyli-4-tiomorfo- lino-pteridimi7-Chloro-2- (N-formylpiperidineino) -6-phenyl-4-thiomorpho- Lino-pteridine
Liuokseen, jossa on 7,6 g (0,02 moolia) 2,7-dikloori- 6- fenyyli-4-tiomorfolino-pteridiiniä 100 ml:ssa dioksaania, lisätään 5,5 g (0,048 moolia) N-formyyli-piperatsiinia 10 ml:ssa dioksaania, ja annetaan sekoittua 1 tunti 40°C:ssa. Sen jälkeen lisätään reaktioseos 600 ml:aan vettä, sakka erotetaan imulla ja kiehautetaan etikkahappoesterin kanssa. Saanto: 88 % teoreettisesta,To a solution of 7.6 g (0.02 mol) of 2,7-dichloro-6-phenyl-4-thiomorpholinopteridine in 100 ml of dioxane is added 5.5 g (0.048 mol) of N-formylpiperazine. ml of dioxane, and allowed to stir for 1 hour at 40 ° C. The reaction mixture is then added to 600 ml of water, the precipitate is filtered off with suction and boiled with acetic acid ester. Yield: 88% of theory,
•J Sulamispiste: 223-226°C• J Melting point: 223-226 ° C
Esimerkin C mukaisesti saadaan seuraavat yhdisteet: " 7-kloori-4-(N-formyylipiperatsino)-4-(1-oksidotiomorfΟ Ι ino ) -6 -p teridiini *. Saanto: 90 % teoreettisesta,According to Example C, the following compounds are obtained: "7-chloro-4- (N-formylpiperazino) -4- (1-oxidothiomorphino) -6-teridine *. Yield: 90% of theory,
Sulamispiste: 230°C (hajoaa) 7- kloori-2-(N-formyylipiperatsino)-4-morfolino-6-fenyyli- ** pteridiiniMelting point: 230 ° C (decomposes) 7-chloro-2- (N-formylpiperazino) -4-morpholino-6-phenyl-pteridine
Saanto: 90 % teoreettisesta, .. Sulamispiste: 247°C (hajoaa) « · • · 7-kloori-2-(N-forinyylipiperatsino)-6-fenyyli-4-piperidino- • · .. pteridiini ,· Saanto: 66 % teoreettisesta, “ 82696Yield: 90% of theory, .. Melting point: 247 ° C (decomposes) «· • · 7-chloro-2- (N-forinylpiperazino) -6-phenyl-4-piperidino- · · .. pteridine, · Yield: 66 % of theoretical, “82696
Sulamispiste: 210-213°C (etikkahappoesteri) 7-kloori-4-dimetyyliamino-2-(N-formyylipiperatsino)-6- fenyyli-pteridiiniMelting point: 210-213 ° C (acetic acid ester) 7-chloro-4-dimethylamino-2- (N-formylpiperazino) -6-phenyl-pteridine
Saanto: 89 % teoreettisesta,Yield: 89% of theory,
Sulamispiste: 232-234°C (etikkahappoesteri) 7-kloori-2-(N-formyylipiperatsino)-4-(N-metyyli-2'- hydroksietyyliamino)-6-fenyyli-pteridiiniMelting point: 232-234 ° C (acetic acid ester) 7-chloro-2- (N-formylpiperazino) -4- (N-methyl-2'-hydroxyethylamino) -6-phenyl-pteridine
Saanto: 86 % teoreettisesta,Yield: 86% of theory,
Sulamispiste: sintrautuu 170°C:sta lähtien 7-kloori-2-(N-formyylipiperatsino)-4-(N-metyyli-bentsyyli- amino)-6-fenyyli-pteridiiniMelting point: sintered from 170 ° C 7-chloro-2- (N-formylpiperazino) -4- (N-methylbenzylamino) -6-phenylpteridine
Saanto: 63 % teoreettisesta,Yield: 63% of theory,
Sulamispiste: 143-145°C (etikkahappoesteri) 7-kloori-2-(N-formyylipiperatsino)-6-fenyyli-4-pyrrolidino- pteridiiniMelting point: 143-145 ° C (acetic acid ester) 7-chloro-2- (N-formylpiperazino) -6-phenyl-4-pyrrolidinopteridine
Saanto: 60 % teoreettisesta,Yield: 60% of theory,
Sulamispiste: 210°C (hajoaa) 7-kloori-2-(N-formyylipiperatsino)-6-fenyyli-4-tiatsolidino-;'· pteridiiniMelting point: 210 ° C (decomposes) 7-chloro-2- (N-formylpiperazino) -6-phenyl-4-thiazolidino - pteridine
Saanto: 82 ?ί teoreettisesta, k·. Sulamispiste: 180-190°C (etikkahappoesteri)Yield: 82? Ί from theoretical, k ·. Melting point: 180-190 ° C (acetic acid ester)
Esimerkki DExample D
2-kloori-4.7-dimorfolino-pteridiini ’* 7,4 ς (0,025 moolia) 2,7-dikloori-4-morfolino-pteridiiniä ;* liuotetaan 150 ml:aan metyleenikloridia ja sekoitetaan ;.· 4,4 g:n kanssa (0,05 moolia) morfoliinia 15 minuuttia 40°C:ssa. Sen jälkeen annetaan jäähtyä, lisätään 200 ml 15 82696 vettä, orgaaninen faasi erotetaan, kuivataan natriumsul-faatilla ja haihdutetaan tyhjössä. Jäännös kiteytetään uudelleen etanolista.2-chloro-4,7-dimorpholino-pteridine * 7.4 ς (0.025 mol) 2,7-dichloro-4-morpholino-pteridine * dissolved in 150 ml of methylene chloride and mixed with 4.4 g (0.05 moles) morpholine for 15 minutes at 40 ° C. It is then allowed to cool, 200 ml of water are added, the organic phase is separated off, dried over sodium sulphate and evaporated in vacuo. The residue is recrystallized from ethanol.
Saanto: 5 7 % t e o reettisestä,Yield: 5 7% of the ethical,
Sulamispiste: 253-255°LMelting point: 253-255 ° L
Esimerkin D mukaisesti saadaan seuraavat yhdisteet: 7-bentsyyliamino-2-kloori-4-piperidino-pteridiini Saanto: 94 % teoreettisesta,According to Example D, the following compounds are obtained: 7-benzylamino-2-chloro-4-piperidino-pteridine Yield: 94% of theory,
Sulamispiste: 220-222°C (dioksaani) 4-bentsyyliamino-2-kloori-7-(l-oksidotiomorfolino)- pteridiiniMelting point: 220-222 ° C (dioxane) 4-benzylamino-2-chloro-7- (1-oxidothiomorpholino) pteridine
Saanto: 45 % teoreettisesta,Yield: 45% of theory,
Sulamispiste: 264-265°C (etanoli) 7-bentsyyliamino-2-kloori-4-(l-oksidotiomorfolino)- pteridiiniMelting point: 264-265 ° C (ethanol) 7-benzylamino-2-chloro-4- (1-oxidothiomorpholino) pteridine
Saanto: 65 % teoreettisesta, *: Sukiamispiste : 239-240°C (dioksaani/etanoli ) :: 2-kloori-4-(N-metyyli-2'-hydroksietyyliamino)-7- ··· morfolino-pteridiini .·. Saanto: 74 % teoreettisesta,Yield: 65% of theory, *: Flash point: 239-240 ° C (dioxane / ethanol) :: 2-chloro-4- (N-methyl-2'-hydroxyethylamino) -7- ··· morpholino-pteridine. Yield: 74% of theory,
V Sulamispiste: 190-192°CV Melting point: 190-192 ° C
7-bentsyyliamino-2-kloori-4-(N-metyyli-2'-hydroksi- etyyliamino)-pteridiini7-Benzylamino-2-chloro-4- (N-methyl-2'-hydroxy-ethylamino) -pteridine
Saanto: 66 % teoreettisesta, • ·Yield: 66% of theory, • ·
..· Sulamispiste: 169-170°C.. · Melting point: 169-170 ° C
·· 2-kloori-4-(N-metyyli-2'-hydroksietyyliamino)-7-tiomor- fo 1ino-pteridiini . . Saanto: 80 % teoreettisesta, is 82696·· 2-Chloro-4- (N-methyl-2'-hydroxyethylamino) -7-thiomorpholino-pteridine. . Yield: 80% of theory, is 82696
Sulamispiste: 214-215°CMelting point: 214-215 ° C
7-bentsyyliamino-2-kloori-4-dietanoliarnino-pteridiini Saanto: 79 % teoreettisesta,7-Benzylamino-2-chloro-4-diethanolamino-pteridine Yield: 79% of theory,
Sulamispiste: 188-189°C (dioksaani) 2-kloori-4-dietanoliamino-7-morfolino-pteridiiniMelting point: 188-189 ° C (dioxane) 2-chloro-4-diethanolamino-7-morpholino-pteridine
Saanto: 74 ?0 teoreettisesta,Yield: 74? 0 of theoretical,
Sulamispiste: 197-199°C (etanoli) 2-kloori-6-metyyli-4,7-dimorfolino-pteridiini Saanto: 29 % teoreettisesta,Melting point: 197-199 ° C (ethanol) 2-chloro-6-methyl-4,7-dimorpholino-pteridine Yield: 29% of theory,
Sulamispiste: 195-200°CMelting point: 195-200 ° C
2-kloori-6-metyyli-4-morfolino-7-tiomorfolino-pteridiini Saanto: 27 % teoreettisesta,2-chloro-6-methyl-4-morpholino-7-thiomorpholino-pteridine Yield: 27% of theory,
Sulamispiste: 150-1S5°CMelting point: 150-1S5 ° C
Esimerkki 1 4,7-dimorfolino-2-piperatsino-.pteridiini 4,2 g (0,0125 molia) 2-kloori-4,7-dimorfolino-pteridiiniä I* liuotetaan 200 ml:aan dimetyylieulfoksidia ja sekoitetaan liuoksen kanssa, jossa on 10,8 g (0,125 moolia) vedetöntä piperatsiinia, 1 tunti huoneen lämpötilassa. Sen jälkeen lisätään 1 1 vettä ja uutetaan kaksi kertaa 100 ml:lla metyleenikloridia. Orgaaniset faasit kuivataan natrium-sulfaatilla ja haihdutetaan pyöröhaihduttimessa. Jäännös pestään eetterillä.Example 1 4,7-Dimorpholino-2-piperazino-pteridine 4.2 g (0.0125 mol) of 2-chloro-4,7-dimorpholino-pteridine I * are dissolved in 200 ml of dimethyl sulfoxide and mixed with a solution of 10.8 g (0.125 mol) of anhydrous piperazine, 1 hour at room temperature. Then 1 l of water are added and the mixture is extracted twice with 100 ml of methylene chloride. The organic phases are dried over sodium sulfate and evaporated on a rotary evaporator. The residue is washed with ether.
Saanto: 85 % teoreettisesta,Yield: 85% of theory,
Sulamispiste: 257-259°C (hajoaa) task.: C 55,94 H 6,78 N 24,00Melting point: 257-259 ° C (decomposes) m.p .: C 55.94 H 6.78 N 24.00
Saatu: 56,26 6,90 23,60 • · Xmax (etanoli): 380, 279, 248 nm « n 82696Found: 56.26 6.90 23.60 • · Xmax (ethanol): 380, 279, 248 nm «n 82696
Esimerkki 2 7-bentsyyliamino-2-piperatsino-4-piperidino-pteridiini 5.3 g (0,015 moolia) 7-bentsyyliamino-2-kloori-4-piperidino-pteridiiniä liuotetaan 250 ml:aan kloroformia ja keitetään refluksoiden liuoksen kanssa, jossa on 10,3 g (0,12 moolia) piperatsiinia. Kahden tunnin kuluttua ravistellaan 200 ml:n kanssa vettä ja orgaaninen faasi kuivataan natriumsulfaatilla ja haihdutetaan tyhjössä. Jäännös kiteytetään uudelleen dioksaanista.Example 2 7-Benzylamino-2-piperazino-4-piperidino-pteridine 5.3 g (0.015 mol) of 7-benzylamino-2-chloro-4-piperidinopteridine are dissolved in 250 ml of chloroform and refluxed with a solution of 10. 3 g (0.12 moles) of piperazine. After 2 hours, shake with 200 ml of water and dry the organic phase over sodium sulfate and evaporate in vacuo. The residue is recrystallized from dioxane.
Saanto: 79 % teoreettisesta,Yield: 79% of theory,
Sulamispiste: 185-188°C task.: C 65,32 H 6,98 N 27,70Melting point: 185-188 ° C m.p .: C 65.32 H 6.98 N 27.70
Saatu: 65,21 7,35 27,46Found: 65.21 7.35 27.46
Amax (etanoli ): 570, 280, 242 nmAmax (ethanol): 570, 280, 242 nm
Esimerkki 3 4-bentsyyliamino-1 -(l-oksidotiomorfolino)-2-piperatsino-• pteridiiniExample 3 4-Benzylamino-1- (1-oxidothiomorpholino) -2-piperazino-pteridine
Valmistetaan esimerkin 2 mukaisesti 4-bentsyyliamino-2-kloori-7-(1-oksidotiomorfoiino)-pteridiinistä ja piperatsiinista.Prepared according to Example 2 from 4-benzylamino-2-chloro-7- (1-oxidothiomorpholino) -pteridine and piperazine.
:: Saanto: 85 % teoreettisesta,:: Yield: 85% of theory,
Sulamispiste: 190-192°C (metanoli)Melting point: 190-192 ° C (methanol)
Lask.: C 57,51 H 5,98 N 25,55 S 7,31Calc .: C 57.51 H 5.98 N 25.55 S 7.31
Saatu: 57,35 6,12 25,29 7,24Found: 57.35 6.12 25.29 7.24
Amax (etanoli): 375, 275, 247 nm ·· E simerkki 4 7-bentsyyliamino-4-(l-oksidotiomorfolino)-2-piperatsino- ·.: pteridiini • ·Amax (ethanol): 375, 275, 247 nm ·· E Example 4 7-Benzylamino-4- (1-oxidothiomorpholino) -2-piperazino- ·: pteridine • ·
Valmistetaan esimerkin 2 mukaisesti 7-bentsyyliamino- i * 18 82696 2-kloori-4-(1-oksidotiomorfolino)-pteridiinistä ja piperat-siinista.Prepared according to Example 2 from 7-benzylamino-18 82696 2-chloro-4- (1-oxidothiomorpholino) -pteridine and piperazine.
Saanto: 90 S teoreettisesta,Yield: 90 S of theory,
Sulamispiste: 239-261°C (metanoli)Melting point: 239-261 ° C (methanol)
Lask.: C 57,32 H 5,40 N 25,55 S 7,31 Saatu: 57,46 5,84 25,60 7,66 ^max (etanoli): 375, 286, 247 nmCalculated: C 57.32 H 5.40 N 25.55 S 7.31 Found: 57.46 5.84 25.60 7.66 λmax (ethanol): 375, 286, 247 nm
Esimerkki 5 4-(N-metyyli-2l-hydroksietvyliamino)17-morfolino-2-piperat- sino-pteridiiniExample 5 4- (N-Methyl-2'-hydroxyethylamino) 17-morpholino-2-piperazino-sino-pteridine
Valmistetaan esimerkin 2 mukaisesti 2-kloori-4-(N-metyyli-2'-hydroksietyyliamino)-7-morfolino-pteridiinistä ja piperatsiinista.Prepared according to Example 2 from 2-chloro-4- (N-methyl-2'-hydroxyethylamino) -7-morpholino-pteridine and piperazine.
Saanto: 78 % teoreettisesta,Yield: 78% of theory,
Sulamispiste: 172-174°C Lask.: C 54,53 H 7,00 N 29,93Melting point: 172-174 ° C Calc .: C 54.53 H 7.00 N 29.93
Saatu: 54,.68 7,40 29,64 \max (etanoli): 384, 278, 247 nmFound: 54.68 7.40 29.64 λ max (ethanol): 384, 278, 247 nm
Esimerkki 6 I 7-bentsyyliamino-4-(N-metyyli-2l-hydroksietyyliamino)-2- piperatsino-pteridiiniExample 6 I 7-Benzylamino-4- (N-methyl-2'-hydroxyethylamino) -2-piperazino-pteridine
Valmistetaan esimerkin 2 mukaisesti 7-bentsyyliamino-2-kloori-4-(N-metyyli-2'-hydroksietyyliamino)-pteridiinistä ja piperatsiinista.Prepared according to Example 2 from 7-benzylamino-2-chloro-4- (N-methyl-2'-hydroxyethylamino) -pteridine and piperazine.
*: Saanto: 70 % teoreettisesta,*: Yield: 70% of theory,
Sulamispiste: 220-222°C Lask.: C 60,84 H 6,64 N 28,41Melting point: 220-222 ° C Calc .: C 60.84 H 6.64 N 28.41
Saatu: 61,03 6,45 28,12Found: 61.03 6.45 28.12
Xmax (etanoli): 372, 277, 243 nm •Λmax (ethanol): 372, 277, 243 nm •
Esimerkki 7 19 82696 4-(N-metyyli-2l-hydroksietyyliamino)-2-piperatsino-7- tiomorfolino-pteridiiniExample 7 19 82696 4- (N-Methyl-2'-hydroxyethylamino) -2-piperazino-7-thiomorpholino-pteridine
Valmistetaan esimerkin 2 mukaisesti 2-kloori-4-(N-inetyyli-2'-hydroksietyyliamino)-7-tiomorfolino-pteridiinistä ja piperatsii riista.Prepared according to Example 2 from 2-chloro-4- (N-methyl-2'-hydroxyethylamino) -7-thiomorpholino-pteridine and piperazine.
Saanto: 65 % teoreettisesta,Yield: 65% of theory,
Sulamispiste: 175-177°CMelting point: 175-177 ° C
Lask.: C 52,28 H 6,71 N 28,70 S 8,21Calc .: C 52.28 H 6.71 N 28.70 S 8.21
Saatu: 52,06 6,44 28,42 8,35 λ max (etanoli): 384, 278, 247 nmFound: 52.06 6.44 28.42 8.35 λ max (ethanol): 384, 278, 247 nm
Esimerkki 8 7-bentsyyliamino-4-dietanoliamino-2-piperatsino- pteridiiniExample 8 7-Benzylamino-4-diethanolamino-2-piperazinopteridine
Valmistetaan esimerkin 2 mukaisesti 7-bentsyyliamino-’· 2-kloori-4-dietanoliamino-pteridiinistä ja piperatsiinista.Prepared according to Example 2 from 7-benzylamino-2-chloro-4-diethanolamino-pteridine and piperazine.
Saanto: 76 % teoreettisesta,Yield: 76% of theory,
·.’ Sulamispiste: 203-208°C·. ’Melting point: 203-208 ° C
\\‘ Lask.: C 59,42 H 6,65 N 26,40Calculated: C 59.42 H 6.65 N 26.40
Saatu: 59,24 6,76 26,24 \max (etanoli): 372, 278, 243 nmFound: 59.24 6.76 26.24 λmax (ethanol): 372, 278, 243 nm
Esimerkki 9 4-dietanoliamino-7-morfolino-2-piperatsino-pteridiini * Valmistetaan esimerkin 2 mukaisesti 2-kloori-4-dietanoli- ** amino-7-morfolino-pteridiinistä ja piperatsiinista.Example 9 4-Diethanolamino-7-morpholino-2-piperazino-pteridine * Prepared according to Example 2 from 2-chloro-4-diethanol- ** amino-7-morpholino-pteridine and piperazine.
.. Saanto: 62 “g teoreettisesta, ·· Sulamispiste: 187-195°C 1 2“ 82696.. Yield: 62 “g of theoretical, ·· Melting point: 187-195 ° C 1 2“ 82696
Lask. : C 53,46 H 6,98 N 27,70Lask. : C 53.46 H 6.98 N 27.70
Saatu: 53,11 6,94 27,53Found: 53.11 6.94 27.53
Amax (etanoli): 382, 278, 247 nmΛmax (ethanol): 382, 278, 247 nm
Esimerkki 10 6-rnetyyli-4,7-dimurfolino-2-piperatsino-pteridiiniExample 10 6-Methyl-4,7-dimurfolino-2-piperazino-pteridine
Valmistetaan esimerkin 2 mukaisesti 2-kloori-6-metyyli- 4,7-dimorfolino-pteridiinistä ja piperatsiinista.Prepared according to Example 2 from 2-chloro-6-methyl-4,7-dimorpholino-pteridine and piperazine.
Saanto: 66 % teoreeettisesta,Yield: 66% of theory,
Sulamispiste: 180-185°C Lask. : C 56,98 H 7,05 N 27,98Melting point: 180-185 ° C Calc. : C 56.98 H 7.05 N 27.98
Saatu: 56,78 6,78 27,70Found: 56.78 6.78 27.70
Amax (etanoli): 382, 279, 248 nmΛmax (ethanol): 382, 279, 248 nm
Esimerkki 11 6-metyyli-4-morfolino-2-piperatsino-7-tiomorfolino~ pteridiini « · • · · • · ' .1 Valmistetaan esimerkin 2 mukaisesti 2-kloori-6-metyyli- • 1 • · ,** 4-mo r f o 1 ino-7 -1 iomo r f o 1 ino-p te ridiinis t ä ja piperatsiinista.Example 11 6-Methyl-4-morpholino-2-piperazino-7-thiomorpholino-pteridine 1 · Prepared according to Example 2 2-chloro-6-methyl- • 1 • ·, ** 4- mo rfo 1 ino-7 -1 iomo rfo 1 ino-pyridine and piperazine.
• « i *”· Saanto: 58 % teoreettisesta,• «i *” · Yield: 58% of theory,
. ·- · Su lamis piste: 185-188°C. · - · Su Lamis point: 185-188 ° C
• » : Lask.: C 54,77 H 6,78 N 26,90 S 7,70 :Y Saatu: 54,99 7,05 26,69 7,93• »: Calculated: C 54.77 H 6.78 N 26.90 S 7.70: Y Found: 54.99 7.05 26.69 7.93
Amax (etanoli): 382, 280, 247 nmΛmax (ethanol): 382, 280, 247 nm
Esimerkki 12 **t 4-(N-metyyli-2l-hydroksietyyliamino)-7-(l-oksidotiomor- . folino)-2-piperatsino-pteridiini • · · « · 1 *;1· 2,92 g 4-(N-mety y 1 i-2 '-hydroksietyy liamino )-7-1 iomor- · ** fo1ino-2-piperatsino-pteridiiniä liuotetaan 50 mlraan • · · · ·· · • · li · 21 82696 metyleenikloridia ja sekoitetaan 2 tuntia huoneen lämpötilassa liuoksen kanssa, jossa 1,72 g m-klooriperbentsoehappoa.Example 12 ** 4- (N-methyl-2'-hydroxyethylamino) -7- (1-oxidothiomorpholino) -2-piperazino-pteridine • · · «· 1 *; 1 · 2.92 g of 4- ( Dissolve N-methyl-2'-hydroxyethylamino) -7-1 isomor- [2-fluoro-2-piperazino-pteridine in 50 ml of 21 82696 methylene chloride and stir for 2 hours. at room temperature with a solution of 1.72 g of m-chloroperbenzoic acid.
Sen jälkeen haihdutetaan pyöröhaihduttimessa ja jäännös pestään eetterillä. Jäännös liuotetaan pieneen määrään vettä, säädetään alkaliseksi 2N natriumhydroksidi11 a ja sen jälkeen uutetaan mety1eenikloridi11 a. Orgaaniset faasit kuivataan ja haihdutetaan pyöröhaihduttimessa.It is then evaporated on a rotary evaporator and the residue is washed with ether. The residue is dissolved in a small amount of water, made alkaline with 2N sodium hydroxide11a and then extracted with methylene chloride11a. The organic phases are dried and evaporated on a rotary evaporator.
Saanto: 1,1 g (36 % teoreettisesta),Yield: 1.1 g (36% of theory),
Sulamispiste: 223-226°C Lask. : C 50,23 H 6,45 S 7,Θ8Melting point: 223-226 ° C Calc. : C 50.23 H 6.45 S 7, Θ8
Saatu; 49,93 6,42 8,03Found; 49.93 6.42 8.03
Amax (etanoli): 386, 278, 245 nmAmax (ethanol): 386, 278, 245 nm
Esimerkki 13 7-bentsyyliamino-2-(N-formyylipiperatsino)-6-fenyyli-4- tiomorfolino-pteridiini 3,2 g (7 millimoolia) 7-kloori-2-(N-formyylipiperatsino)-6-fenyyli-4-tiomorfolino-pteridiiniä ja 2,2 g (21 millimoolia) bentsyy1iamiinia kuumennetaan refluksoiden 15 ml:ssa di-oksaania. 3 tunnin kuluttua liuotin poistetaan tyhjössä ja öljymäinen jäännös kaadetaan 100 ml:aan vettä. Saostunut ,·. tuote otetaan talteen, kuivataan ja kromatografoidaan lyhyessä piihappogeelipylväässä etikkahappoetyyliesteri/ I metanolilla 15:1. Sen jälkeen aine kiteytetään uudelleen etikkahappoesteristä.Example 13 7-Benzylamino-2- (N-formylpiperazino) -6-phenyl-4-thiomorpholino-pteridine 3.2 g (7 mmol) of 7-chloro-2- (N-formylpiperazino) -6-phenyl-4-thiomorpholino -pteridine and 2.2 g (21 mmol) of benzylamine are heated to reflux in 15 ml of dioxane. After 3 hours, the solvent is removed in vacuo and the oily residue is poured into 100 ml of water. Precipitated,. the product is recovered, dried and chromatographed on a short column of silica gel with acetic acid ethyl ester / l methanol 15: 1. The material is then recrystallized from acetic acid ester.
Saanto: 80 % teoreettisesta,Yield: 80% of theory,
Sulamispiste: Z18-221°CMelting point: Z18-221 ° C
Esimerkin 13 mukaisesti saadaan seuraavat yhdisteet: 2-(N-formyylipiperatsino)-7-(N-metyyli-2'-hydroksietyyli-amino)-6-fenyyli-4-tiomorfolino-pteridiini ·· Saanto: 55 % teoreettisesta,According to Example 13, the following compounds are obtained: 2- (N-formylpiperazino) -7- (N-methyl-2'-hydroxyethylamino) -6-phenyl-4-thiomorpholino-pteridine ·· Yield: 55% of theory,
Sulamispiste: sintrautuu 130°C:sta lähtien (etikkahappoesteri) »·» • ♦ 22 82696 2-(N-formyylipiperatsino)-4-mofolino-7-(l-oksidotiomor- folino)-6-fenyyli-pteridiiniMelting point: sintered from 130 ° C (acetic acid ester) »·» • ♦ 22 82696 2- (N-formylpiperazino) -4-mofolino-7- (1-oxidothiomorpholino) -6-phenyl-pteridine
Saanto: 50 % teoreettisesta,Yield: 50% of theory,
Sulamispiste: 250-252°C (vesi) 2-(N-formyylipiperatsino)-4-(N-metyyli-2'-hydroksietyyli- amino)-7-morfolino-6-fenyyli-pteridiiniMelting point: 250-252 ° C (water) 2- (N-formylpiperazino) -4- (N-methyl-2'-hydroxyethylamino) -7-morpholino-6-phenyl-pteridine
Saanto: 80 % teoreettisesta,Yield: 80% of theory,
Sulamispiste: 165-175°CMelting point: 165-175 ° C
2-(N-formyylipiperatsino)-7-(N-metyyli-bentsyyliamino)-4-(N-metyyli-2'-hydroksi-etyyliamino)-6-fenyyli-pteridiini Saanto: 80 % teoreettisesta,2- (N-formylpiperazino) -7- (N-methylbenzylamino) -4- (N-methyl-2'-hydroxyethylamino) -6-phenylpteridine Yield: 80% of theory,
Sulamispiste: 135-155°CMelting point: 135-155 ° C
2-(N-formyylipiperatsino)-4-(N-metyyli-2'-hydroksietyyli- amino)-7-tiornorfolino-6-fenyyli-pteridiini2- (N-Formylpiperazino) -4- (N-methyl-2'-hydroxyethylamino) -7-thiornorpholino-6-phenyl-pteridine
Saanto: 80 % teoreettisesta,Yield: 80% of theory,
Sulamispiste: sintrautuu 155°C:sta lähtien 4,7-di-(N-metyyii-bentsyyliamino)-2-(N-formyylipiperatsino)- : 6-fenyy 1 i-pteridiini a · · * Saanto: 50 % teoreettisesta,Melting point: sintered from 155 ° C 4,7-di- (N-methylbenzylamino) -2- (N-formylpiperazino) -: 6-phenyl-pteridine α · · * Yield: 50% of theory,
Sulamispiste: 60-70°CMelting point: 60-70 ° C
7-dimetyyliamino-2-(N-formyylipiperatsino)-4- (N-metyyli- • · i.i : bentsyyliamino)-6-fenyyli-pteridiini : : : Saanto: 90 % teoreettisesta,7-Dimethylamino-2- (N-formylpiperazino) -4- (N-methyl- • benzylamino) -6-phenyl-pteridine: Yield: 90% of theory,
Sulamispiste: sintrautuu 90°C:sta lähtien 2-(N-formyylipiperatsino)-4-(N-metyyli-bentsyyliamino)-7-... morfolino-6-fenyyli-pteridiiniMelting point: sintered from 90 ° C 2- (N-formylpiperazino) -4- (N-methylbenzylamino) -7-morpholino-6-phenylpteridine
Saanto: 80 % teoreettisesta, ·. . Sulamispiste: sintrautuu 40°C:sta lähtien Φ * ···»· • « >1Yield: 80% of theory,. . Melting point: sintered from 40 ° C Φ * ··· »· •«> 1
Esimerkki IAExample IA
23 8 2 6 9 6 7-bentsyyliaroino-6-fenyyli-2-piperatsino-4-tiomorfolino- pteridiini 1,58 g (3 millimoolia) 7-bentsyyliamino-2-(N-formyyli-piperatsi no)-6-fenyy1i-4-1iomorfoiino-pteridiiniä ja 15 ml 10-prosenttista suolahappoa kuumennetaan refluksoiden 30 minuuttia. Jäähdyttämisen jälkeen liuokseen lisätään vesipitoista kaliumkarbonaattiliuosta ja uutetaan tuote kloroformilla. Orgaaninen faasi haihdutetaan tyhjössä ja tuote kromatografoidaan piihappogeelillä metanoli/väkevällä ammoniakilla (80:1).23 8 2 6 9 6 7-Benzylamino-6-phenyl-2-piperazino-4-thiomorpholinopteridine 1.58 g (3 mmol) of 7-benzylamino-2- (N-formylpiperazino) -6-phenyl- 4-Thiomorpholinopteridine and 15 ml of 10% hydrochloric acid are heated at reflux for 30 minutes. After cooling, aqueous potassium carbonate solution is added to the solution, and the product is extracted with chloroform. The organic phase is evaporated in vacuo and the product is chromatographed on silica gel with methanol / concentrated ammonia (80: 1).
Saanto: 0,8 g (54 % teoreettisesta),Yield: 0.8 g (54% of theory),
Sulamispiste: 115-130°C task.: C 65,03 H 6,06 N 22,47Melting point: 115-130 ° C m.p .: C 65.03 H 6.06 N 22.47
Saatu: 65,20 6,22 22,07Found: 65.20 6.22 22.07
Xmax (etanoli): 386, 292, 248 nmΛmax (ethanol): 386, 292, 248 nm
Esimerkki 15 7-(N-metyyli-2,-hydroksietyyliamino)-6-fenyyli-2-pipe- ratsino-4-tiomorfolino-pteridiini ;:· Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipiperatsino)- 7-(N-metyyli-2'-hydroksietyyliamino)-6-fenyyli-4-tiomor~ fo 1ino-pteridiinistä.Example 15 7- (N-methyl-2, -hydroxyethylamino) -6-phenyl-2-piperazino-4-thiomorpholino-pteridine: · Prepared according to Example 14 2- (N-formylpiperazino) -7- (N- methyl 2'-hydroxyethylamino) -6-phenyl-4-thiomorpholino-pteridine.
Saanto: 52 % teoreettisesta,Yield: 52% of theory,
Sulamispiste: sintrautuu 70°C:sta lähtien task.: C 59,20 H 6,48 N 24,02Melting point: sintered from 70 ° C onwards: C 59.20 H 6.48 N 24.02
Saatu: 59,44 6,22 23,85Found: 59.44 6.22 23.85
Xmax (etanoli): 400, 297, 258 nmΛmax (ethanol): 400, 297, 258 nm
Esimerkki 16 . . 4-morfolino-7-(l-oksidotiomorfolino)“‘6-fenyyli-2-pipe- ratsino-pteridiini 24 8 2 6 9 6Example 16. . 4-Morpholino-7- (1-oxidothiomorpholino) '' 6-phenyl-2-piperazino-pteridine 24 8 2 6 9 6
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipiperatsino)-4-morfolino-7-(l-oksdiotiomorfolino)-6-fenyyli-pteridiinistä. Saanto: 43 % teoreettisesta^ .Prepared according to Example 14 from 2- (N-formylpiperazino) -4-morpholino-7- (1-oxdiothiomorpholino) -6-phenyl-pteridine. Yield: 43% of theory.
Sulamispiste: 196-199°CMelting point: 196-199 ° C
task.: C 58,28 H 6,11 N 22,66 S 6,48 Saatu: 57,93 6,31 22,72 6,44task: C 58.28 H 6.11 N 22.66 S 6.48 Found: 57.93 6.31 22.72 6.44
Amax (etanoli): 400, 295, 258 nmAmax (ethanol): 400, 295, 258 nm
Esimerkki 17 4-(N-metyyli-2'-hydroksietyyliamino)-7-morfolino-6-fenyyli-2-piperatsino-pteridiiniExample 17 4- (N-Methyl-2'-hydroxyethylamino) -7-morpholino-6-phenyl-2-piperazino-pteridine
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipiperasti-no)-4-(N-metyyli-2'-hydroksietyyliamino)-7-morfolino- 6- fenyyli-pteridiinistä.Prepared according to Example 14 from 2- (N-formylpiperastino) -4- (N-methyl-2'-hydroxyethylamino) -7-morpholino-6-phenyl-pteridine.
Saanto: 31 % teoreettisesta.Yield: 31% of theory.
Sulamispiste: sintrautuu 90°C:sta lähtien Lask.: C 61,30 H 6,71 N 24,87Melting point: sintered from 90 ° C Calc .: C 61.30 H 6.71 N 24.87
Saatu: 61,52 6,73 24,75Found: 61.52 6.73 24.75
Xmax (etanoli): 398, 296, 258 nmΛmax (ethanol): 398, 296, 258 nm
Esimerkki 18 7- (N-metyyli-bentsyyliamino)-4-(N-metyyli-2l-hydroksietyyli+ * amino)-6-fenyyli-2-piperatsino-pteridiiniExample 18 7- (N-Methyl-benzylamino) -4- (N-methyl-2'-hydroxyethyl + * amino) -6-phenyl-2-piperazino-pteridine
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipiperatsi- no)-7-(N-metyyli-bentsyyliamino)-4-(N-metyyli-2'-hydroksi- etyyliamino)-6-fenyyli-pteridiinistä.Prepared according to Example 14 from 2- (N-formylpiperazino) -7- (N-methyl-benzylamino) -4- (N-methyl-2'-hydroxyethylamino) -6-phenyl-pteridine.
Saanto: 19 % teoreettisesta,Yield: 19% of theory,
Sulamispiste: 80-110°C .* Lask. : C 66,91 H 6,66 N 23,13Melting point: 80-110 ° C. : C 66.91 H 6.66 N 23.13
Saatu: 66,80 6,58 22,70Found: 66.80 6.58 22.70
Xmax (etanoli): 395, 294, 258 nm » ·Λmax (ethanol): 395, 294, 258 nm »·
Esimerkki 19 25 8 2 6 9 6 4-(N-metyyli-2'-hydroksietyyliamino)-6-fenyyli-2-pipe- ratsinu-7-Liotnorfol-i.no-pteridiiniExample 19 25 8 2 6 9 6 4- (N-methyl-2'-hydroxyethylamino) -6-phenyl-2-piperazine-7-liotnorphol-1-n-pteridine
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyyli-piperatsino)-4- (N-inetyy li-2'-hydroksietyyliamino)-6-fenyyli-7-tiomorfolino-pteridiinistä.Prepared according to Example 14 from 2- (N-formyl-piperazino) -4- (N-methyl-2'-hydroxyethylamino) -6-phenyl-7-thiomorpholino-pteridine.
Saanto: 13 % teoreettisesta,Yield: 13% of theory,
Sulamispiste: 100-140°C Lask. : C 59,20 H 6,48 N 24,02Melting point: 100-140 ° C Calc. : C 59.20 H 6.48 N 24.02
Saatu: 59,66 6,45 23,74 max (etanoli): 398, 296, 258 nmFound: 59.66 6.45 23.74 max (ethanol): 398, 296, 258 nm
Esimerkki 20 4,7-bis-(N-metyyli-bentsyyliamino)-6-fenyyli-2-pipe- ratsino-pteridiirnExample 20 4,7-Bis- (N-methyl-benzylamino) -6-phenyl-2-piperazino-pteridine
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipipe-ratsino)-4,7-bis-(N-metyylibentsyyliamino)-6-fenyyli-. ; pteridiinistä.Prepared according to Example 14 from 2- (N-formylpiperazino) -4,7-bis- (N-methylbenzylamino) -6-phenyl-. ; pteridines.
Saanto: 56 % teoreettisesta,Yield: 56% of theory,
Sulamispiste: hartsimainen tuote Lask. : C 72,47 H 6,46 N 21,12 ·; Saatu: 72,60 6,62 20,90 : 1 Amax (etanoli): 398, 294, 258 nmMelting point: resinous product Calc. : C 72.47 H 6.46 N 21.12 ·; Found: 72.60 6.62 20.90: 1 Amax (ethanol): 398, 294, 258 nm
Esimerkki 21 7-dimetyyliamino-4-(N-metyyli-bentsyyliamino)-6-fenyyli-** 2-piperatsino-pteridiini .. Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipipe- ratsino)-7-dimetyyliamino-4-(N-metyyli-bentsyyliamino)- 6 - fenyy1i-pteridiin istä.Example 21 7-Dimethylamino-4- (N-methyl-benzylamino) -6-phenyl - ** 2-piperazino-pteridine. Prepared according to Example 14 2- (N-formylpiperazino) -7-dimethylamino-4- ( N-methyl-benzylamino) -6-phenyl-pteridine.
Saanto: 69 % teoreettiseta, • 26 8 2 6 9 6Yield: 69% without theory, • 26 8 2 6 9 6
Sulamispiste; 129-132°C (etikkahappoesteri)Melting point; 129-132 ° C (acetic acid ester)
Lask. : C 68,69 H 6,65 N 24,65Lask. : C 68.69 H 6.65 N 24.65
Saatu: 68,84 6,81 24,37 ;ymax (etanoli); 396, 294, 258 nmFound: 68.84 6.81 24.37, ymax (ethanol); 396, 294, 258 nm
Esimerkki 22 4-(N-metyyli-bentsyyliamino)-7-morfolino-6-fenyyli-2- piperatsino-pteridiiniExample 22 4- (N-Methyl-benzylamino) -7-morpholino-6-phenyl-2-piperazino-pteridine
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipipe- rat&ino)-4-(N-metyyli-brietsyyliamino)-7-morfolino-6- fenyyli-pteridiinistä.Prepared according to Example 14 from 2- (N-formylpiperino) -4- (N-methyl-briecylamino) -7-morpholino-6-phenyl-pteridine.
Saanto: 60 ?ί teoreettisesta,Yield: 60% of theoretical,
Sulamispiste: 7D-100°C task.: C 67,71 H 6,50 N 22,57Melting point: 7D-100 ° C m.p .: C 67.71 H 6.50 N 22.57
Saatu: 67,96 6,49 22,55 \max (etanoli): 396, 294, 258 nmFound: 67.96 6.49 22.55 λ max (ethanol): 396, 294, 258 nm
Esimerkki 23 7-dimetyyliamino-6-fenyyli-2-piperatsino-4-pyrrolidino- pteridiiniExample 23 7-Dimethylamino-6-phenyl-2-piperazino-4-pyrrolidinopteridine
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipipe- ra t s i no ) -7-dime t y y 1 iamino-6-f eny y li-4-py rrol idino- pteridiinistä.Prepared according to Example 14 from 2- (N-formylpiperazine) -7-dimethylamino-6-phenyl-4-pyrrolidinopteridine.
Saanto: 30 % teoreettisesta,Yield: 30% of theory,
Sulamispiste: 125-130°C Lask.: C 59,20 H 6,48 N 24,02Melting point: 125-130 ° C Calc .: C 59.20 H 6.48 N 24.02
Saatu: 59,44 6,71 23,65Found: 59.44 6.71 23.65
Xmax (etanoli): 394, 294, 257 nm 1 ψ » » -Λmax (ethanol): 394, 294, 257 nm 1 ψ »» -
Esimerkki 24 27 82696 7-morfolino-6-fenyyli-2-piperat3ino-4-tiatsolidino- pteridiiniExample 24 27 82696 7-Morpholino-6-phenyl-2-piperazino-4-thiazolidinopteridine
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyylipipe-ratsino)-7-morfolino-6-fenyyli-4-tiatsolidino-pteridiinistä. Saanto: 56 % teoreettisesta,Prepared according to Example 14 from 2- (N-formylpiperazino) -7-morpholino-6-phenyl-4-thiazolidinopteridine. Yield: 56% of theory,
Sulamispiste: 12U-150°CMelting point: 12U-150 ° C
task.: C 59,46 H 6,07 N 24,12 S 6,90 Saatu: 59,13 6,13 24,36 6,68task: C 59.46 H 6.07 N 24.12 S 6.90 Found: 59.13 6.13 24.36 6.68
Aitiax (etanoli): 396, 294, 258 nmAliacia (ethanol): 396, 294, 258 nm
Esimerkki 25 7-mQrfolino-4-(l-oksidotiatsolidino)-6-fenyyli-2-pipe- ratsino-pteridiini 0,93 g (2 millimoolia) 7-morfolino-6-fenyy1i-2-piperat-sino-4-1iatso 1idino-pteridiiniä liuotetaan 15 mitään di-oksaania ja kuumennetaan 1,5 tuntia refluksoiden 0,86 g:n kanssa na t r i umrrie t ap er j odaa 11 ia 5 ml:ssa vettä. Sen jälkeen haihdutetaan pyöröhaihduttimessa, jäännös otetaan : : kloroformiin ja kiomatografoidaan piihappogeelipylväässä etanoli/ammoniakilla (25:1).Example 25 7-Morpholino-4- (1-oxidothiazolidino) -6-phenyl-2-piperazino-pteridine 0.93 g (2 mmol) of 7-morpholino-6-phenyl-2-piperazino-4-thiazole 1-Dino-pteridine is dissolved in 15% dioxane and heated at reflux for 1.5 hours with 0.86 g in 11 ml of 5 ml of water. It is then evaporated on a rotary evaporator, the residue is taken up in chloroform and chromatographed on a silica gel column with ethanol / ammonia (25: 1).
Saanto: 31 % teoreettisesta,Yield: 31% of theory,
Sulamispiste: 19U-250°C Lask. : C 57,49 H 5,87 S 6,67Melting point: 19U-250 ° C Calc. : C 57.49 H 5.87 S 6.67
Saatu: 57,24 6,10 7,15Found: 57.24 6.10 7.15
Xmax (etanoli): 394, 290, 258 nmΛmax (ethanol): 394, 290, 258 nm
Esimerkki 26 4-(N-metyyli-2>-hydroksietyyliamino)-7-(1-oksidotiomor-folino)-6-fenyyli-2-piperat3ino-pteridiiniExample 26 4- (N-Methyl-2H-hydroxyethylamino) -7- (1-oxidothiomorpholino) -6-phenyl-2-piperazino-pteridine
Valmistetaan esimerkin 25 mukaisesti 4- (N-metyyli-2 ' » 28 8 2 6 9 6 hydroksietyyliamino)-7-tiomorfolino-6-fenyyli-2-piperatsino-pteridiinistä.Prepared according to Example 25 from 4- (N-methyl-2 ', 28 8 2 6 9 6 hydroxyethylamino) -7-thiomorpholino-6-phenyl-2-piperazino-pteridine.
Saanto: 58 % teoreettisesta,Yield: 58% of theory,
Sulamispiste: sintrautuu 110°C:sta lähtien task. : C 57 , 25 H 6,27 S 6,64Melting point: sintered from 110 ° C onwards. : C 57, 25 H 6.27 S 6.64
Saatu: 57,45 6,59 6,96Found: 57.45 6.59 6.96
Xmax (etanoli): 396, 296, 255 nmΛmax (ethanol): 396, 296, 255 nm
Esimerkki 27 4,7-bis-dimetyyliamino-6-fenyyli-2-piperatsino-pteridiiniExample 27 4,7-Bis-dimethylamino-6-phenyl-2-piperazino-pteridine
Valmistetaan esimerkin 14 mukaisesti 4,7-bis-dimetyy 1 i-amino-2-(N-formyylipiperatsino)-6-fenyyli-pteridiinistä. Saanto: 85 % teoreettisesta.Prepared according to Example 14 from 4,7-bis-dimethyl-amino-2- (N-formylpiperazino) -6-phenyl-pteridine. Yield: 85% of theory.
Sulamispiste: sintrautuu 50°C:sta lähtien Lask.: C 63,46 H 6,93 N 29,61Melting point: sintered from 50 ° C Calc .: C 63.46 H 6.93 N 29.61
Saatu: 63,22 7,07 29,82Found: 63.22 7.07 29.82
Xmax (etanoli): 394, 293, 257 nm • " Esimerkki 28 6-fenyyli-2-piperatsino-4.7-dipiperidino-pteridiiniΛmax (ethanol): 394, 293, 257 nm • "Example 28 6-Phenyl-2-piperazino-4,7-dipiperidinopteridine
Valmistetaan esimerkin 14 mukaisesti 2-(N-formyyli-: . piperatsino )-6-fenyy1i-4,7-dipiperidino-pteridiinistä.Prepared according to Example 14 from 2- (N-formyl-piperazino) -6-phenyl-4,7-dipiperidinopteridine.
Saanto: 43 ?ί teoreettisesta,Yield: 43? Ί from theoretical,
Sulamispiste: sintrautuu 90°C:sta lähtien Lask. : C 68 ,10 H 7,47 N 24,43Melting point: sintered from 90 ° C Calc. : C 68, 10 H 7.47 N 24.43
Saatu: 68,00 7,47 24,29Found: 68.00 7.47 24.29
Xmax (etanoli): 400, 299, 260 nm • ·Λmax (ethanol): 400, 299, 260 nm • ·
Esimerkki 29 29 8 2 6 9 6 2.7- dipiperatsino-4-morfolino-6-fenyyli-pteridiini 25,2 g (0,07 moolia) 2,7-dikloori-4-morfolino-6-fenyyli-pteridiiniä 70 ml:ssa etanolia ja 36 g piperatsiinia sekoitetaan 1 tunti huoneen lämpötilassa. Sen jälkeen seos sekoitetaan 700 ml:aan vettä, muodostunut sakka erotetaan imulla, liuotetaan 4 N etikkahappoon ja saostetaan uudelleen Θ N natriumhydroksidilla .Example 29 29 8 2 6 9 6 2.7-Dipiperazino-4-morpholino-6-phenyl-pteridine 25.2 g (0.07 mol) of 2,7-dichloro-4-morpholino-6-phenyl-pteridine in 70 ml ethanol and 36 g of piperazine are stirred for 1 hour at room temperature. The mixture is then stirred in 700 ml of water, the precipitate formed is filtered off with suction, dissolved in 4N acetic acid and reprecipitated with ΘN sodium hydroxide.
Saanto: 24 g (74 % teoreettisesta),Yield: 24 g (74% of theory),
Sulamispiste: sintrautuu 130°C:sta lähtien Lask.: C 62,44 H 6,77 N 27,31Melting point: sintered from 130 ° C Calc .: C 62.44 H 6.77 N 27.31
Saatu: 62,78 6,70 27,31Found: 62.78 6.70 27.31
Xmax (etanoli'. 400, 298 260 nmΛmax (ethanol '. 400, 298 260 nm
Esimerkki 30 2.7- dipiperatsino-4-tiomorfolino-6-fenyyli-pteridiiniExample 30 2.7-Dipiperazino-4-thiomorpholino-6-phenyl-pteridine
Valmistetaan esimerkin 29 mukaisesti 2,7-dikloori-4-tiomorfolino-6-fenyyli-pteridiinistä.Prepared according to Example 29 from 2,7-dichloro-4-thiomorpholino-6-phenyl-pteridine.
; Saanto: 79 % teoreettisesta,; Yield: 79% of theory,
Sulamispiste: sintrautuu 80OC:s^a lähtien Lask. : C 60 35 H 6,54 N 6,71Melting point: sintered from 80 ° C Calc. : C 60 35 H 6.54 N 6.71
Saatu: 60,20 6,67 6,92 λ max (etanoli): 400, 299, 259 nmFound: 60.20 6.67 6.92 λ max (ethanol): 400, 299, 259 nm
Esimerkki 31 7-morfolino-4-(l-oksidotiomorfolino)-6-fenyyli-2- piperatsino-pteridiini 4,6 g (0,01 moolia) 7-kloori-2-(N-formyylipiperatsino)-4-(1-oksidotiomorfo 1ino)-6-fenyy1i-pteridiiniä 8,7 dsssa (0,1 moolia) morfoliinia kuumennetaan 1 tunti 100°C:ssa.Example 31 7-Morpholino-4- (1-oxidothiomorpholino) -6-phenyl-2-piperazino-pteridine 4.6 g (0.01 mol) of 7-chloro-2- (N-formylpiperazino) -4- (1- oxidothiomorpholino) -6-phenyl-pteridine in 8.7 ds (0.1 mol) of morpholine is heated for 1 hour at 100 ° C.
30 8269630 82696
Liuos haihdutetaan tyhjössä ja jäännös kromatografoidaan piihappogeelipy1 väessä metanoli/ammoniakilla (50:1). Saanto: 1,5 g (30 % teoreettisesta),The solution is evaporated in vacuo and the residue is chromatographed on silica gel with methanol / ammonia (50: 1). Yield: 1.5 g (30% of theory),
Sulamispiste: 15l-154°C (metanoli)Melting point: 15-154 ° C (methanol)
Lask.: C 58,28 H o,il N 22,66 S 6,48 Saatu: 57,99 6,13 22,22 6,65 λ max (etanoli): 398, 294, 258 nmCalc .: C 58.28 H o, il N 22.66 S 6.48 Found: 57.99 6.13 22.22 6.65 λ max (ethanol): 398, 294, 258 nm
Esimerkki 32 7-bentsyyliamino-4-(l-oksidotiomorfolino)-6-fenyyli-2- piperatsino-pteridiiniExample 32 7-Benzylamino-4- (1-oxidothiomorpholino) -6-phenyl-2-piperazino-pteridine
Valmistetaan esimerkin 31 mukaisesti 7-kloori-2-(N-formyyli-piperatsino)-4-(l-oksidotiomorfolino)-6-fenyyli-pteridiinistä ja bentsyyliamiinista.Prepared according to Example 31 from 7-chloro-2- (N-formyl-piperazino) -4- (1-oxidothiomorpholino) -6-phenyl-pteridine and benzylamine.
Saanto: 50 % teoreettisesta,Yield: 50% of theory,
Sulamispiste: 200°C (haj.)Melting point: 200 ° C (dec.)
Lask.: C 63,01 H 5,88 N 21,77 S 6,23 caatu: 62,89 6,07 21,45 6,20Calc .: C 63.01 H 5.88 N 21.77 S 6.23 Caatu: 62.89 6.07 21.45 6.20
Esimerkki 33 ·* 7-bentsyyliamino-4-morfolino-6-fenyyli-2-piperatsino- uteridiiniExample 33 · * 7-Benzylamino-4-morpholino-6-phenyl-2-piperazino-uteridine
Valmistetaan esimerkin 31 mukaisesti 7-kloori-2-(N-formyyli-piperatsino)-4-morfolino-6-fenyyli-pteridiinistä ja bentsyyliamiinista.Prepared according to Example 31 from 7-chloro-2- (N-formyl-piperazino) -4-morpholino-6-phenyl-pteridine and benzylamine.
Saanto: 35 % teoreettisesta,Yield: 35% of theory,
Lask.: C 67,20 H 6,27 N 23,22Calc .: C 67.20 H 6.27 N 23.22
Saatu: 67,25 6,34 23,42Found: 67.25 6.34 23.42
Xmax (etanoli): 385, 290, 248 nmΛmax (ethanol): 385, 290, 248 nm
Esimerkki 34 31 82696 4t7-dimorfolino-6-Fenyyli-2-piperats.ino-pteridiiniExample 34 31 82696 4'-Dimorpholino-6-phenyl-2-piperazino-pteridine
Valmistetaan esimerkin 31 mukaisesti 7-kloori-2-(N-formyyli-piperatsino)-4-morfolino-6-fenyyli-pteridiinistä ja morfo 1iinis ta.Prepared according to Example 31 from 7-chloro-2- (N-formyl-piperazino) -4-morpholino-6-phenyl-pteridine and morpholine.
Saanto: 13 % teoreettisesta,Yield: 13% of theory,
Sulamispiste: 220-223°C Lask.: C 62,32 H 6,34 N 24,23Melting point: 220-223 ° C Calc .: C 62.32 H 6.34 N 24.23
Saatu: 62,21 6,64 24,05Found: 62.21 6.64 24.05
Amax (etanoli): 400, 296, 259 nmAmax (ethanol): 400, 296, 259 nm
Esimerkki 35 4,7-bis-(l-oksidotiomorfolino)-6-fenyyli-2-piperatsino- pteridiiniExample 35 4,7-Bis- (1-oxidothiomorpholino) -6-phenyl-2-piperazinopteridine
Valmistetaan esimerkin 31 mukaisesti 7-kloori-2-(N-formyyli-piperatsino)-4-(l-ok8idotiomorfolino)-6-fenyyli-pteridiinistä ja 1-oksidotiomorfoliinista.Prepared according to Example 31 from 7-chloro-2- (N-formyl-piperazino) -4- (1-oxidothiomorpholino) -6-phenyl-pteridine and 1-oxidothiomorpholine.
. Saanto: 25 % teoreettisesta,. Yield: 25% of theory,
Sulamispiste: 250°C (hajoaa)Melting point: 250 ° C (decomposes)
Lask.: C 54,73 H 5,74 N 24,28Calc .: C 54.73 H 5.74 N 24.28
Saatu: 54,60 5,71 24,04Found: 54.60 5.71 24.04
Amax (etanoli): 400, 296, 259 nmAmax (ethanol): 400, 296, 259 nm
Claims (3)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843445298 DE3445298A1 (en) | 1984-12-12 | 1984-12-12 | NEW PTERIDINE, METHOD FOR THE PRODUCTION AND USE THEREOF AS INTERMEDIATE PRODUCTS OR AS A MEDICINAL PRODUCT |
| DE3445298 | 1984-12-12 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI854862A0 FI854862A0 (en) | 1985-12-10 |
| FI854862A7 FI854862A7 (en) | 1986-06-13 |
| FI82696B true FI82696B (en) | 1990-12-31 |
| FI82696C FI82696C (en) | 1991-04-10 |
Family
ID=6252576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI854862A FI82696C (en) | 1984-12-12 | 1985-12-10 | PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PROPERTIES OF PTERIDINER. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0185259A3 (en) |
| JP (1) | JPS61140585A (en) |
| AU (1) | AU576924B2 (en) |
| CA (1) | CA1252783A (en) |
| DE (1) | DE3445298A1 (en) |
| DK (1) | DK161327C (en) |
| ES (1) | ES8707238A1 (en) |
| FI (1) | FI82696C (en) |
| GR (1) | GR852996B (en) |
| IL (1) | IL77294A (en) |
| NO (1) | NO161373C (en) |
| NZ (1) | NZ214522A (en) |
| PH (1) | PH24451A (en) |
| PT (1) | PT81650B (en) |
| ZA (1) | ZA859462B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276506B2 (en) | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| BR0211310A (en) * | 2001-06-28 | 2006-10-31 | Pliva D D | heterocyclic compounds and their uses as d-alanyl, d-alanine ligase inhibitors |
| DE10202468A1 (en) * | 2002-01-23 | 2004-09-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Pteridine derivatives, process for their preparation and their use |
| ES2295897T3 (en) * | 2003-08-29 | 2008-04-16 | 4 Aza Ip Nv | IMMUNODEPRESSING EFFECTS OF PTERIDINE DERIVATIVES. |
| DK1673092T3 (en) * | 2003-10-17 | 2007-12-17 | 4 Aza Ip Nv | Heterocyclyl-substituted pteridine derivatives and their use in therapy |
| GB2407089A (en) * | 2003-10-17 | 2005-04-20 | 4 Aza Bioscience Nv | Pteridine derivatives |
| AU2005221614A1 (en) * | 2004-03-04 | 2005-09-22 | Neurogen Corporation | Arylalkylamino-substituted quinazoline analogues |
| DE102004057618A1 (en) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted pteridines for the treatment of inflammatory diseases |
| DE102004057595A1 (en) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted pteridines for the treatment of inflammatory diseases |
| DE102004057594A1 (en) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitute pteridine for the treatment of inflammatory diseases |
| DE102004057645A1 (en) * | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New substituted pteridine compounds, useful as phosphodiesterase 4 inhibitors for treating e.g. inflammatory diseases, cancer, asthma, ulcerative colitis, depression and schizophrenia |
| PL1954699T3 (en) * | 2005-11-22 | 2013-01-31 | Kudos Pharm Ltd | PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| RU2445315C2 (en) * | 2005-11-22 | 2012-03-20 | Кудос Фармасьютиклз Лимитед | PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AND USE THEREOF AS mTOR INHIBITORS |
| JP5440934B2 (en) | 2006-05-24 | 2014-03-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Substituted pteridine |
| WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| US10144736B2 (en) | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| NZ575672A (en) | 2006-08-23 | 2011-10-28 | Kudos Pharm Ltd | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors |
| EA019092B1 (en) | 2008-06-20 | 2014-01-30 | Астразенека Аб | PROCESS FOR PREPARATION OF PYRIDO-PYRIMIDIN mTOR KINASE INHIBITORS AND SALT FORMS THEREOF |
| HUE038059T2 (en) | 2015-03-04 | 2018-10-29 | Gilead Sciences Inc | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| US10370342B2 (en) | 2016-09-02 | 2019-08-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| ES2826748T3 (en) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivatives of 4,6-diamino-pyrido [3,2-d] pyrimidine as modulators of Toll-like receptors |
| TWI751517B (en) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
| TW202210480A (en) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
| TWI879779B (en) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | Processes for preparing toll-like receptor modulator compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3159628A (en) * | 1962-05-28 | 1964-12-01 | Smith Kline French Lab | Pteridine-5-oxide derivatives |
| DE3323932A1 (en) * | 1983-07-02 | 1985-01-10 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW 2-PIPERAZINO-PTERIDINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND |
-
1984
- 1984-12-12 DE DE19843445298 patent/DE3445298A1/en not_active Withdrawn
-
1985
- 1985-12-05 EP EP85115459A patent/EP0185259A3/en not_active Ceased
- 1985-12-10 FI FI854862A patent/FI82696C/en not_active IP Right Cessation
- 1985-12-11 NO NO854965A patent/NO161373C/en unknown
- 1985-12-11 PH PH33161A patent/PH24451A/en unknown
- 1985-12-11 ZA ZA859462A patent/ZA859462B/en unknown
- 1985-12-11 DK DK572685A patent/DK161327C/en not_active IP Right Cessation
- 1985-12-11 PT PT81650A patent/PT81650B/en not_active IP Right Cessation
- 1985-12-11 JP JP60278859A patent/JPS61140585A/en active Pending
- 1985-12-11 ES ES549806A patent/ES8707238A1/en not_active Expired
- 1985-12-11 CA CA000497336A patent/CA1252783A/en not_active Expired
- 1985-12-11 IL IL77294A patent/IL77294A/en unknown
- 1985-12-11 NZ NZ214522A patent/NZ214522A/en unknown
- 1985-12-12 GR GR852996A patent/GR852996B/el unknown
- 1985-12-12 AU AU51232/85A patent/AU576924B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FI854862A0 (en) | 1985-12-10 |
| EP0185259A3 (en) | 1989-03-01 |
| DK572685D0 (en) | 1985-12-11 |
| PT81650B (en) | 1988-04-21 |
| GR852996B (en) | 1986-04-16 |
| ES549806A0 (en) | 1987-07-16 |
| DK572685A (en) | 1986-06-13 |
| DK161327C (en) | 1991-12-09 |
| DK161327B (en) | 1991-06-24 |
| DE3445298A1 (en) | 1986-06-12 |
| NZ214522A (en) | 1988-07-28 |
| AU576924B2 (en) | 1988-09-08 |
| ZA859462B (en) | 1987-07-29 |
| ES8707238A1 (en) | 1987-07-16 |
| NO161373C (en) | 1989-08-09 |
| PH24451A (en) | 1990-06-25 |
| CA1252783A (en) | 1989-04-18 |
| FI82696C (en) | 1991-04-10 |
| NO854965L (en) | 1986-06-13 |
| AU5123285A (en) | 1986-06-19 |
| FI854862A7 (en) | 1986-06-13 |
| NO161373B (en) | 1989-05-02 |
| JPS61140585A (en) | 1986-06-27 |
| PT81650A (en) | 1986-01-01 |
| EP0185259A2 (en) | 1986-06-25 |
| IL77294A (en) | 1989-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI82696B (en) | PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PROPERTIES OF PTERIDINER. | |
| AU640289B2 (en) | New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them | |
| Rewcastle et al. | Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids | |
| FI80454B (en) | PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PROPERTIES OF 2-PIPERAZINO-PTERIDINER. | |
| HU198033B (en) | Process for production of n-benzhydril-diaz-cycloalkilalcane-anilides and medical preparatives containing these compounds as active substance | |
| JPH06179673A (en) | New piperazine and homopiperazine derivative, medicinal composition containing these compound and production of these compound | |
| El-Gendy et al. | Synthesis of heterobicyclic nitrogen systems bearing a 1, 2, 4-triazine moiety as anticancer drugs: part IV | |
| PL119520B1 (en) | Process for preparing novel,condensed pyrimidine derivatives pirimidina | |
| KR900005836B1 (en) | 1,2,4-triazolo(4,3-c)pyrimidines | |
| US4560685A (en) | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics | |
| EP2142506B1 (en) | Novel benzophenone hybrids as potential anticancer agents and a process for the preparation thereof | |
| US3764598A (en) | Pyrimidopyridazine derivatives | |
| US4303790A (en) | 2-Amino-4-imino-6-hydrazinopyrimidine | |
| Taylor et al. | Synthesis of Some [1, 2, 3] Thiadiazolo [5, 4-d] pyrimidines and Pyrimido [4, 5-b][1, 4] thiazines1 | |
| Revanasiddappa et al. | Synthesis and biological studies of some novel schiff bases and hydrazones derived from 8-hydroxy quinoline moiety | |
| LeMahieu et al. | Synthesis and antiallergy activity of 5-oxo-5H-thiazolo [2, 3-b] quinazolinecarboxylic acids | |
| KR920000271B1 (en) | 1,2,4,-triazoro |1.5-c¨ pyrimidine and its preparation process | |
| Mekheimer et al. | 1, 8-Naphthyridines II: Synthesis of novel polyfunctionally substituted 1, 8-naphthyridinones and their degradation to 6 aminopyridones | |
| DE2361757A1 (en) | Cardioactive imidazopyridines - substd. 2-phenyl 1H(or3H) imidazo (4,5,6) pyridines with positive inotropic and platelet aggregation inhibiting activity | |
| US4511721A (en) | Intermediate for preparing antifungal 1,2-dihydropyrido[3,4-b]-pyrazines | |
| JPH07626B2 (en) | Substituted triazine compound | |
| DeCroix et al. | Pteridines from. alpha.-phenyl-N, N-dimethylacetamidine | |
| Temple Jr et al. | Methylation and amination of folic acid | |
| US3763163A (en) | 4-(n,o-disubstituted-hydroxylamino)-quinazolines | |
| Unangst | Synthesis of some 2‐amino‐4‐phenyl‐3H‐1, 5‐benzodiazepines by reaction of aromatic diamines and acetylenic imidates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: DR. KARL THOMAE GESELLSCHAFT MIT |